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Dengue Virus (DENV) is known as the causative agent of Dengue Fever and Dengue 
Hemorrhagic Fever / Dengue Shock Syndrome (DHF/ DSS). Infection with one of the 
serotypes elicits long-term, homotypic protection but does not protect from the risk of 
development of DHF/DSS upon subsequent infection with other serotype(s) via a 
mechanism known as Antibody-Dependent Enhancement (ADE) by cross-reactive, 
non-neutralizing antibodies. Previous studies using mouse mAbs demonstrated that 
the Ectodomain III (EDIII) in the E protein of DENV is the primary target of the most 
potent neutralizing antibodies against DENV. Interestingly, the EDIII-specific 
antibodies are much less abundant than the EDI/II-specific antibodies, although they 
may contribute more significantly to viral neutralization and protection. This study 
aims to characterize the binding specificity of human convalescent serum from a 
DENV-2-immune subject, and the potential change in its neutralizing capacity after 
antibody depletion, to elucidate the role of EDIII in DENV neutralization. In addition, 
Phage Display Technology was utilized to generate a DENV-immune Fab phage 
library for investigation of antibody repertoire upon infection, and for identification of  
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1.1. BACKGROUND ON DENGUE VIRUS  
 
1.1.1 Epidemiology, diagnosis and pathogenesis 
 
Dengue Virus infection is a leading emerging arboviral disease that is a major global 
health problem, with highest incidence in the tropical and subtropical countries. 
According to WHO in 2009, there were an estimated 2.5 billion people at risk of 
infection, mainly in Southeast and South Asian, Caribbean, as well as Central and 
South American regions. Almost 100 million cases of dengue infection are reported 
each year, with an estimated 500000 cases manifesting into severe, life-threatening 
dengue diseases, including Dengue Haemorrhagic Fever (DHF) and Dengue Shock 
Syndrome (DSS) (2, 3). The rapid increase in the emergence of the disease is likely 
the result of increase in human population, rapid urbanization, continued challenges in 
the implementation of effective vector controls, and international air and sea travel.  
 
Dengue viruses are transmitted to human beings through the bite of infected 
mosquitoes of the Aedes genus (Ae. aegypti and Ae. albopictus). Transmission by Ae. 
aegypti tends to be associated with sharp epidemics in contrast to the less efficient 
transmission by Ae. albopictus that results in a slow-moving outbreak (4).  
 
Ae aegypti has been highly adapted to urban environments, and the uncontrolled 
urbanization occurring in many developing parts of the world enhances the expansion 
of the mosquito population, making vector control more challenging. The prevalent 
peridomestic water containers, discarded plastics, and unused tyres in such setting, 
especially at building projects, are likely to be exploited by mosquitoes for the habitat 
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for its larvae. This results in more widespread breeding sites (not just domestic sites 
or houses as previously known). This corresponds to the age profile shift of dengue in 
Asia and in Latin America lately as adults (working population) are increasingly 
affected, whereas in the past, children tend to bear the major burden of the disease (5-
8). 
 
The clinical features of dengue virus infection can range from an asymptomatic 
infection to a self-limiting dengue fever, to severe cases of DHF/DSS, which has a 
higher risk of occurring in secondary infection with a different DENV serotype. The 
severe manifestations are characterized by high fever, bleeding, increased vascular 
permeability/ rapid onset of capillary leakage, liver enlargement/ damage (indicated 
by elevation in the levels of liver enzymes aspartate aminotransferase and alanine 
aminotransferase), circulatory failure, accompanied by thrombocytopenia and 
haemoconcentration. Complications such as gastrointestinal bleeding can also occur 
in some cases (9, 10).  
 
The intrinsic virulence of the dengue virus strains, the host innate response to viral 
infections as well as other host factors such as genetic factors, nutritional status, 
ethnicity, and underlying chronic disease could also be additional factors that 
determine the severity of the pathogenesis of dengue virus infection (reviewed in 
(11)). 
 
Neutralizing antibody responses that develop after a dengue infection with a serotype 
is believed to provide lifelong protection against re-infection with the same serotype. 
In addition to the humoral/ antibody response, dengue-specific cellular immunity also 
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confers a long-term protection, although the roles and the mechanisms are less clearly 
defined.  DENV-specific T lymphocytes may have a role in viral clearance by the 
killing of virus-infected cells and secreting the pro-inflammatory cytokines to limit 
the infection. The roles of cellular immunity and humoral immunity must be equally 
taken into consideration in designing any model of protection (e.g. vaccine) against 
DENV. However, this study is focused on the humoral aspect of immunity following 
DENV infection, more specifically the role and the identification of highly 
neutralizing antibodies in DENV convalescent human serum. 
 
 
1.1.2 Antibody-Dependent Enhancement (ADE) 
 
DENV has four antigenically similar but immunologically distinct serotypes, namely 
DENV1, 2, 3, and 4. Infection with one serotype can elicit the production of 
antibodies that are cross-reactive with all four serotypes in a short term but will only 
provide long-term protection against the serotype that caused the initial infection, i.e. 
homotypic protection (11-13). 
 
During subsequent infection with a different serotype of DENV, an individual may be 
at a greater risk of developing more severe form of the disease, Dengue Hemorrhagic 
Fever/ Dengue Shock Syndrome (DHF/DSS). Through a mechanism known as 
Antibody Dependent Enhancement (ADE), these cross-reactive, non-neutralizing 
antibodies bind to the virus and form immune complexes that are taken into target 
cells that bear the Fcϒ-receptor such as monocytes/ macrophages, and thereby 
increase the productive infection (11, 14, 15). 
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The requirement for binding of the Fc portion of antibody to induce ADE was 
demonstrated by Balsitis et al, whereby the use of Fab and non- Fcϒ-receptor  binding 
variant (N297Q)  resulted in the neutralization of infection instead of ADE (16). 
Furthermore, subprotective levels of antibody have been shown to enhance the 
severity of dengue infection in mice model. For neutralization to occur, the affinity of 
the antibody to the epitopes on the surface of the virus and its concentration need to 
be sufficiently high. This was demonstrated by the increased survival time as a result 
of neutralization by MAb 4G2 at high doses, but significantly enhanced the infection 
and reduced the mean survival time when it was administered at low doses (17). 
 
 
1.1.3 Structural perspective, replication and life cycle 
 
Dengue Virus (DENV) is a member of Flaviviridae family, and is categorized under 
the flavivirus genus (18). The genome of DENV consists of a single positive-sense 
RNA strand packaged by virus capsid protein in a host-derived lipid bilayer (18, 19). 
The 11 kb genome has an open reading frame, translated as a polyprotein, which is 
subsequently cleaved by cellular signal peptidase and viral proteases to yield three 
structural proteins (C, prM and E) and seven non-structural proteins (NS1, NS2A/B, 
NS3, NS4A/B, and NS5) (18). The structural proteins constitute the virus particle, and 
the non-structural proteins are required for viral genome replication.  
 
Attachment of DENV to host cell is mediated by several known surface receptors, 
such as DC-SIGN (Dendritic-cell-specific ICAM-grabbing non-integrin, which is a 
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mannose-specific lectin that interacts with the carbohydrate residues on the DENV E 
Protein), GRP78/BiP (glucose-regulating protein 78) and CD14-associated molecules 
(20-23). Following attachment and entry into the host cell via receptor-mediated 
endocytosis, acidification of the endosomal vesicle triggers the conformational 
changes in the E protein, resulting in the fusion of the viral and host cell membranes 
(Figure 1). 
 
After fusion, the virus undergoes disassembly to release the positive-sense, single-
stranded RNA genome into the host cytoplasm. This RNA is translated immediately 
into a single polyprotein, that is subsequently processed by viral and host proteases. 
The positive-sense genome is copied to make negative-sense RNA, which is 
replicated by viral RNA polymerase to synthesize more viral genomes to be packaged 
in the newly generated virions and more mRNAs for translation into viral proteins 
(18).  
 
The genome replication occurs on intracellular membranes, followed by the assembly 
of the virus particles on the Endoplasmic Reticulum (ER) surface. This assembly of 
structural proteins and newly synthesized single stranded RNA genome buds into the 
lumen of the ER, forming a non-infectious, immature viral particle. The trans-Golgi 
network transports it to the plasma membrane of the host cell where it is undergoes 
cleavage by the host protease furin, to form a mature and infectious virion, which is 
subsequently released from the host cell by exocytosis (18, 19).  
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Figure 1. Flavivirus life cycle (adapted from Mukhopadhyay 2005). Upon 
attachment and entry into host cell via RME, conformational changes of the viral 
E Protein drives fusion and disassembly of virus. Genome is released into host 
cytoplasm, replicated or translated into polyprotein.  Virus assembly occurs on ER 
membrane, and immature virions are transported to the host plasma membrane via 
the Golgi network. Virion matures upon cleavage by furin and released from the 
host cell by exocytosis. 
 
 
1.2 ENVELOPE (E) PROTEIN AS TARGET OF FLAVIVIRUS 
NEUTRALIZING ANTIBODY 
 
1.2.1 Overview of the DENV Envelope (E) Protein  
 
The Envelope (E) protein is a component of the structural proteins of Dengue Virus, 
together with the Capsid (C) and the pre-membrane/ membrane (prM/M) proteins. It 
contains a cellular receptor binding site and a fusion peptide, and undergoes pH- 
dependent oligomeric arrangement during fusion. This has been shown in the 
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formation of dimers at neutral pH and irreversible trimerization upon exposure to 
acidic environment of endosome, resulting in the fusion of viral and cell membranes 
(24, 25). The E protein has been shown to be the primary target for neutralizing 
antibodies although antibodies specific for prM and NS proteins have also been 
observed in previous studies (26-28). 
 
The E protein is approximately 500 amino acids in length, which includes the N-
terminal 400 amino acids that form the ectodomain. The crystal structures of the E 
ectodomain of flaviviruses have shown that each E protein monomer consists of three 
β-barrel domains in each. The figure below depicts the dengue virus E protein dimer 
and the 3 domains of each monomer, EDI, II, and III shown as yellow, red and blue 
respectively (Figure 2). Domain I (EDI, red) is a centrally located β-barrel structure 
that connects Domain II and Domain III via flexible hinges which drive 
conformational changes for fusion to occur. Domain II (EDII, yellow) contains the 
highly conserved hydrophobic fusion loop at its distal end (19, 24).  
 
 
     
        (Pierson and Diamond 2009) 
Figure 2. Ribbon diagram of a DENV E protein dimer with Ectodomains (ED)  
I, II and III shown as red, yellow and blue ribbons, respectively. The fusion loop  




Domain III (EDIII, blue), is an Ig-like domain that is thought to contain the putative 
receptor-binding sites and its pH-mediated conformational changes drives the fusion 
between the viral and host cell membrane (26, 29). A crucial role for EDIII in virus 
attachment is supported by the following observations: distal projection of EDIII from 
the virion surface, numbers of mutations that impact virulence or tropism map to 
EDIII, and the effective blocking of DENV2 entry into C6/36 by recombinant WNV-
EDIII (30). Furthermore, the mouse mAb 3H5 (with specificity for EDIII) has been 
shown to block binding of DENV2 to the virus receptors at the attachment stage (31).  
 
                     
1.2.2 Roles of EDIII- reactive antibodies in virus neutralization 
 
Much of the research to elucidate the role of EDIII-reactive antibodies in virus 
neutralization has been performed with EDIII-specific mouse monoclonal antibodies 
(MAbs) (27, 32, 33) (34-36). In general, the strongly neutralizing mouse MAbs are 
serotype-specific and bind to epitopes on EDIII that are unique to each serotype. 
Among a panel of well-characterized E-glycoprotein-specific MAbs, the EDIII-
specific MAbs were shown to block the DENV2 adsoprtion to Vero cells most 
strongly (37, 38). Among the panel of well-characterized EDIII-specific murine 
antibodies in the literature is 9F12, a hybridoma-derived MAb developed in the 
Vasudevan Laboratory.The in vitro neutralization of all four DENV serotypes and 
WNV by 9F12 in plaque reduction assays has been reported recently and further 




The four loops on the upper lateral surface of EDIII have been identified as the likely 
target of many potent neutralizing antibodies. A study by Sukupolvi et al. identified 
the contact residues of several DENV2 EDIII-specific MAbs with distinct neutralizing 
potentials, and showed that the ones with strongest neutralizing activity and less 
cross-reactivity bind to the epitopes on the lateral ridge of EDIII, centered at the 
unique FG loop (Figure 3) (36). 
 
                                   
 
(Sukupolvi-Petty et al 2007) 
Figure 3. EDIII lateral ridge antibody epitope. Structure of DENV-2 EDIII,  
with the corresponding 16 amino acids of the WNV E16 neutralizing antibody  




Although extensive epitope mapping studies have been performed with mouse MAbs 
against DENV, much less has been done with human MAbs to study the interactions 
between DENV and antibody at the molecular level. Nevertheless, the many 
observations on neutralization by antibodies that bind EDIII epitopes in mouse 
models make the potential neutralizing mechanism by the EDIII-specific antibodies 
very attractive to investigate, especially in the DENV human infections. 
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1.2.3 Contribution of EDIII-specific antibodies to virus neutralization in 
human sera  
 
A recent investigation by Wahala et al. was focused on the level and specificity of 
EDIII-reactive antibodies in the convalescent sera of people who have recovered from 
primary and secondary DENV infections, as well as their contribution to DENV 
neutralization (40). They reported the presence of EDIII-reactive antibodies in both 
the primary and secondary DENV-immune human sera. Whereas the EDIII-reactive 
antibodies in the primary immune sera were serotype-specific, the antibodies in the 
secondary immune sera were directed against a cross-reactive epitope on EDIII. This 
was deduced from the observation that most of EDIII reactivity to the second serotype 
was lost when the secondary immune sera were depleted using one serotype’s MBP-
EDIII (40). 
 
The levels of EDIII- reactive antibodies in the convalescent sera samples were low in 
the Wahala et al study (40), leading to the hypothesis that these antibodies only play a 
minor role in neutralization. Strikingly, the change in neutralization titres in EDIII-
depleted sera compared with undepleted sera showed that depletion of EDIII-reactive 
antibodies only resulted in the decrease of neutralization titre by 10-15% (40). 
 
In contrast to the conclusion by Wahala et al (40), observations in a recent study by 
Beltramello et al (28) suggested a more significant role of EDIII-specific MAbs in 
neutralization. Using immortalized memory B cells from individuals that had primary 
or secondary exposures to dengue, a larger panel of anti-DENV MAbs (70 MAbs) 
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was generated. They found that although antibodies with specificity for EDI and EDII 
were most prevalent, MAbs that bind EDIII tended to be more potent in DENV 
neutralization screens (28). This suggests that the EDIII-specific antibodies can 
contribute significantly to DENV protection and neutralization in humans although 
they are less abundant in the repertoire. 
 
To further investigate the role of EDIII-specific antibodies in DENV neutralization, 
this study utilizes sera from a human subject (Subject A) with a complex history of 
flavivirus infection (Figure 5). Our hypothesis is that re-exposure to a virus that has 
been previously cleared by Subject A will lead to boosting of homotypic antibodies 
and determine if there is any difference in antibody distribution (in particular EDIII-
specific antibodies) following re-exposure to the virus.  
 
 
1.3 PHAGE DISPLAY TECHNOLOGY  
 
Phage display technology, as an alternative to the conventional hybridoma 
technology, is a robust method for the in vitro selection of monoclonal antibodies 
against a given antigen. Principally, a protein-encoding (in this case an antibody) is 
fused to a bacteriophage coat protein resulting in phage particles that display the 
antibody on their surface. The coding sequence for each antibody is contained within 
the phage particles thereby providing a direct link between phenotype and genotype 
(reviewed by (41)).  
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Three key advantages of phage display technology are (i) The genotype-phenotype 
link manifested in the physical linkage between the displayed peptide or protein and 
its genetic information that encodes it; (ii) Biopanning is a powerful selection method 
based on the competitive target-specific protein interactions, allowing selection and 
identification of the most efficacious complexes based on the highest relative binding 
affinity; (iii) The versatility of phage library design to display peptides or proteins of 
varying length and complexity (42, 43).  
 
The key steps in the selection of specific antibodies from phage display libraries are 
illustrated in Figure 4. The antigen is firstly immobilized to affinity resin or an 




                       (Smothers, Science 2002) 
Figure 4. Schematic overview of Biopanning: Selection is based on competitive binding, i.e. 
the fab-phage that binds strongly to the immobilized antigen are captured/ selected, whereas 
the unbound phage are eliminated during the rigorous washing procedure. The bound phage 




By using the selected antibodies as the basis for subsequent selection, the affinity of 
the antibodies selected can be further increased to levels unobtainable in the immune 
system, which could be exploited for clinical applications such as in human 
therapeutics and diagnostic (reviewed by (44)). 
 
The most common application of phage display in antibody technology is as a source 
of novel antibodies for a specific target. However, phage display can also be used to 
circumvent the problems associated with cloning MAbs from hybridomas. A common 
problem when cloning a hybridoma is the presence of non-functional heavy or light 
chains that are transcribed from various aberrant mRNAs generated from some 
hybridoma cell lines (45). This problem was encountered in the Vasudevan laboratory 
when attempts were made to clone 9F12 from its hybridoma. The resulting Fab clone 
no longer bound EDIII and was suspected to contain a non-functional heavy chain 
(Dr. Nicole Moreland, personal communication). Using a series of 10 EDIII-specific 
hybridomas as templates (including 9F12), a small chimeric Fab phage library was 
generated by Dr. Nicole Moreland in the Vasudevan Laboratory. The generation and 
amplification of all possible EDIII-specific heavy and light chains may lead to the 
identification of novel Fabs not seen in the original hybridomas. The EDIII 
hybridoma library has been used in this study to investigate EDIII-specific 






1.4 AIMS OF STUDY 
 
The main aims of this study are to re-examine the findings by Wahala et al in the 
neutralizing capacity of EDIII-specific antibodies, as well as to generate an immune 
Fab phage library using Phage Display Technology to investigate the human antibody 













































2.1 PREPARATION OF ANTIGENS 
 
2.1.1 Ectodomain III purified protein from DENV-2 and DENV-3 
 
(i) Protein expression 
Glycerol stock of BL21 E.coli, transformed with T7 plasmid containing EDIII gene 
from DENV-2 TSV01 or DENV-3 H87 (Pet16b Vector (Novagen)) (39) was streaked 
on LB agar plate supplemented with 100mg/mL Ampicilin. Following overnight 
incubation at 37°C, a colony was picked to inoculate LB broth (+Ampicilin). Seeder 
was grown at (37°C, 200rpm) overnight and used to inoculate 1L of LB broth 
(+100mg/mL Ampicilin). The expression culture was incubated on shaker (200rpm, 
37°C) until OD reached 0.7. Isopropyl-β-thio galactopyranoside (IPTG) was added 
into the culture at 1mM concentration, followed by 5 hours of incubation on shaker 
(200rpm, 37°C). Cells were pelleted via centrifugation at 8000g, 15 min, 4°C.  
 
(ii) Refolding by dialysis  
Pellet was resuspended in lysis buffer (20mM Tris-HCl (pH 8.5), 150mM NaCl, 
10mM β-ME, 1xEDTA free protease inhibitor tablet, prior to lysis by sonication. 
Following centrifugation (13000rpm, 20min, 4°C), the insoluble fraction (containing 
inclusion bodies) was washed (by stirring for 20min at RT in 1M Urea, 2% Triton-X-
100). After centrifugation (13000rpm, 20min, 4°C), the pellet was resuspended (in 
20mM Tris-HCl (pH 8.5), 150mM NaCl, 10mM Imidazole, 10mM β-ME) and the 
suspension was stirred at 4°C overnight. The soluble fraction was loaded onto Ni-
NTA column (get details) to trap the His-tagged EDIII proteins), and eluted using a 
gradient of imidazole from 0-500mM. Desired fractions were pooled and diluted to 
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6M Urea with dialysis buffer (200mM Tris pH (8.5), 10mM EDTA, 5mM reduced 
Glutathione, 0.5mM oxidative Glutathione, 100mM Arginine). Protein was dialysed 
with 7000 kDa MW dialysis tube in dialysis buffer overnight at 4°C. Protein was 
further dialyzed in Size Exclusion Chromatography (SEC) buffer (20mM Tris (pH 
8.5), 250mM NaCl) overnight at 4°C. 
 
(iii) Gel filtration  
Protein was concentrated and filtered prior to loading on a Superdex75 gel filtration 
column. Desired fractions were pooled (protein-containing fractions were screened by 
running small aliquots on 15% SDS-PAGE gel at 150V, 60min, stained with 
Coomassie Blue dye), concentrated (using 3000 kDa MW concentrator primed with 
SEC buffer and 10% Glycerol) and quantified by Nanodrop and stored at -80°C. 
Unlike in the studies done previously by Wahala et al (40), The EDIII used in our 
study was expressed with His tag protein, and not as a MBP fusion protein, to ensure 
correct folding and avoid any potential alteration or masking of the antibody epitopes 
on EDIII.  
 
2.1.2 Whole virus antigen 
 
(i) Live virus propagation in mosquito cell line (C6/36) 
Different DENV serotypes (DENV-2 TSV01, DENV-3 H87, DENV-1 EDEN, 
DENV-2 EDEN, DENV-3 EDEN, DENV-4 EDEN, and DENV-2 PDK-53) were 
propagated in C6/36 cell line (Ae. Albopictus-derived). C6/36 cells were cultured in 
RPMI-1640 +13% FCS + Pen-Strep and after forming a confluent monolayer, they 
were infected with the respective serotype/ strain at MOI of 1 (virus stock was diluted 
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in serum-free RPMI-1640) and incubated for 2 hours at 37°C, 5% CO2. The virus-
containing medium was then aspirated and replaced with maintenance medium 
(RPMI-1640 + 5% FCS) and the infected cells were incubated for 5 days at 28°C 
(http://www.atcc.org). The virus supernatant was harvested together with the infected 
C6/36 monolayer that has been trypsinized. Following centrifugation to remove cell 
debris at 4000rpm for 10 min at 4°C, the supernatant was filtered and stored in 
aliquots at  -80°C. 
 
(ii) Preparation of UV-inactivated DENV-2 TSV01 and DENV-3 H87 whole virus 
antigens for ELISA.  
 
a. Concentration and Purification by Sucrose Gradient 
Filtered virus supernatant was concentrated x100 using 100kDA MW 
concentrator (3000g, 4°C). The concentrated virus was then loaded onto the 
sucrose gradient (filter-sterilized 55%, 44%, 33%, 22% and 11% Sucrose, 
overlaid carefully on top of each other with 55% Sucrose solution at the 
bottom of (Beckman ultracentrifuge tube), and all the tubes were centrifuged 
at 75000g, 18hours, 4°C. 0.75mL fractions were collected from each tube, and 
the samples from every fraction were run on 12% SDS-PAGE gel (150V, 1 
hour, stained with Coomassie Blue dye).  
 
b. Western Blot 
Western Blot was also performed to confirm the presence of pure virus 
particles in the pooled fractions. The fractions containing high amount of pure 
virus were pooled. 6µL of virus from respective fraction (that has been boiled 
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at 100°C for 5 min together with 2µL of β-ME-containing 4xgel loading dye) 
was loaded onto each well of 12% SDS-PAGE gel. Gel was run at 120V for 1 
hour. Following transfer of proteins onto membrane (BioRad Wet transfer 
apparatus, Amersham Hybond-P PVDF transfer membrane), membrane was 
blocked overnight in blocking buffer (PBS-T (0.1% Tween-20) +5% milk) at 
4°C on shaker. Membrane was incubated with 9F12 monoclonal antibody 
(diluted in blocking buffer, at final concentration of 10-8 M) for 1 hour at room 
temperature. Following a series of washing, membrane was incubated with 
HRP-conjugated anti-mouse antibody (at 1:5000 dilution) for 1 hour at room 
temperature. Membrane was developed using Amersham Biosciences ECL 
detection kit and analyzed on IQuant. 
 
c. Buffer Exchange and UV Inactivation 
Buffer exchange and concentration (replacement of sucrose-containing 
medium with serum-free RPMI-1640 by centrifuging the pooled fractions at 
3000g, 4°C in 100kDa MWCO concentrator) were performed subsequently. 
Concentrated, purified virus was then inactivated via UV irradiation for 
30min, quantified by Nanodrop, and stored in aliquots at -80°C. 
 
2.2 PLAQUE ASSAY 
 
2.2.1 Maintenance of BHK-21 cells 
 
BHK-21 cells were grown in RPMI-1640 medium containing 1% Pen/Strep and 10% 
FBS, and incubated at 37°C, 5% CO2. Upon reaching confluence, the splitting of cell 
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monolayer was done by incubating the cells with Trypsin-EDTA (Gibco, Invitrogen) 
at 37°C for 2-3 minutes. Cells were centrifuged to remove Trypsin-containing 
medium (900g, 3 min) and resuspended in fresh medium prior to re-seeding. 
 
 
2.2.2 Plaque assay: Virus dilution, Adsorption, Incubation, Fixation, Staining 
 
BHK-21 cells were seeded into 24-well plate (2x105 cells/ well) and incubated 
overnight at 37°C, 5% CO2. Serially diluted virus (1 in 10 dilution), starting from 10-3 
dilution was added onto the respective wells containing the confluent cell monolayer 
upon aspiration of the medium. Each dilution was performed in triplicates. Cell 
control wells (no virus) and virus control wells (neat stock of virus) were included on 
the plate, and were each performed in triplicate. Following incubation (2 hours, 37°C, 
5% CO2, virus samples were aspirated, and 500µL of 0.8 % CMC overlay (0.8% 
methylcellulose (Aquacide 2, Calbiochem), 2x RPMI-1640, 2% FBS, 1% Pen/Strep, 
0.5%NaHCO3, 2.5%v/v 1M HEPES, 0.5% DMSO) was added into each well. Plate 
was incubated for 5 days (the incubation time varies among serotypes) at 37°C, 
5%CO2. Cells were fixed with 3.7% paraformaldehyde, and stained with 1% Crystal 
Violet for plaque visualization. 
 
2.3 PLAQUE REDUCTION & NEUTRALIZATION TEST (PRNT) 
 
BHK-21 cells were seeded into 24-well plate (2x105 cells/ well) and incubated 
overnight at 37°C, 5% CO2. At 90-95% confluence, the preparation of virus/serum 
mix (serially diluted sera + 40 Plaque Forming Units (PFU)/well of DENV-2 TSV01 
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virus, incubated for one hour at 37°C, 5% CO2) was added. The dilutions made for the 
virus controls (VC40, VC20 and VC10) and positive control (undiluted murine 
monoclonal antibody 3H5, which binds to DENV-2) was also included. Each dilution 
was performed in triplicate. Following incubation and aspiration of the virus/serum 
mixture, a nutrient overlay medium (0.8% CMC) was added to each well, and the 
plates were incubated for four days at 37°C, 5% CO2. The cells were subsequently 
fixed and stained with 1% Crystal Violet for plaque visualization. The 50% 
neutralization titre was determined as the dilution of serum at which >50% reduction 
in the number of plaques (in comparison to the virus controls) was observed. The 
same method above was repeated for all the other serotypes, with varying number of 
incubation days. 
 
2.4 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 
 
Nunc flat 96 well immunoplate was coated with 75 ng/well of purified, UV-
inactivated DENV-2 TSV01 or DENV-3 H87 whole virus or 0.1 µg/ well of purified 
EDIII in 50mM Bicarbonate Buffer (pH 9.6) overnight at 4°C. Following blocking 
with blocking buffer (PBS +1% Tween-20 (vol/vol) + 5% milk (wt/vol) + 2% FCS) 
overnight at 4°C or 3 hours at room temperature, washing with PBS-T (0.1% Tween-
20 (vol/vol)), the plate was incubated for 1 hr at room temperature with serially 
diluted human serum or mouse monoclonal antibody (3H5, 4G2 or D11C). After a 
series of washing with PBS-T, the plate was incubated with the secondary antibody 
(HRP-conjugated anti-human or HRP-conjugated anti-mouse for serum or mouse 
monoclonal antibody respectively) for 1 hr at room temperature, and washed three 
times with PBS-T and once with PBS. Tetramethylbenzidine-peroxide (TMB) was 
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added to each well (50 µL/well) and the reaction was allowed to develop in the dark 
prior to arrest with 3M HCl. Absorbance was measured at 450 nm on a 
spectrophotometer.  
 
2.5 CONVALESCENT SERUM PROCESSING 
 
10mL of venous blood was collected in tubes containing clotting agent (BD 
Vacutainer Plus plastic serum tube) and allowed to clot for 30 minutes at room 
temperature, followed by centrifugation at 2500rpm for 20 min. Clear serum was heat 
inactivated at 56°C for 1 hour, and stored in aliquots at -80°C. 
 
2.6 SERUM DEPLETION 
 
Ni-NTA Magnetic agarose beads suspension (Qiagen) with protein binding capacity 
of 30ug/100uL were blocked with 3%FBS in TBS-T (150mM NaCl, 20mM Tris pH 
8.0, 0.1% Tween-20) for 1 hour, 4°C on rotation. Purified His-tagged EDIII protein 
was added in excess to the beads suspension and the mixture was allowed to incubate 
for for 1 hour, 4°C on rotation. Following a series of washing (150mM NaCl, 20mM 
Tris pH 8.0, 10mM Imidazole), and further blocking of beads with 3%FBS in PBS-T 
(pH 7.2) under similar conditions as above, serum (diluted 1:5 in PBS) was added 
onto the EDIII-coated beads and left to incubate overnight at 4°C on rotation. His 
tagged-NS2B-NS3 pro185 was used as control. Beads were pelleted via centrifugation 
(3000g, 2 min, 4°C), and serum sample was collected for subsequent PRNT (methods 
as above). 10µL aliquot from each step of the depletion procedures were run on 15% 
SDS-PAGE gel to ensure that the agarose beads coating, and the capture of antibodies 
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were performed successfully. The complete depletion of EDIII-specific antibodies 
from the serum was further confirmed via ELISA. 
 
2.7 PHAGE LIBRARY 
 
2.7.1 Biopanning of Fab Phage-Display Library 
 
Chimeric Mouse/ Human Ectodomain III (EDIII) Library was screened for phage that 
bind strongly to both immobilised DENV-2 TSV01 whole virus and His-tagged 
DENV-2 TSV01 EDIII protein by a series of biopanning. Four wells on a Maxisorb 
96-well immunoplate (Nunc, USA) were coated with 50 µL/well of 5µg/mL anti-
DENV-2 Rabbit Polyclonal antibody at 4°C overnight. Each well was then blocked 
with 150 µL of 3% BSA in PBS at 37°C for 1 hour. After blocking, 50µL of 40µg/mL 
DENV-2 TSV01 whole virus was added to each well, and the plate was incubated at 
37°C for 2 hours. Alternatively, 50 µL/well of 20µg/mL EDIII protein was used to 
coat four wells on a Maxisorb 96-well immunoplate (Nunc, USA), followed by 
blocking. 50 µL phage was added to each well and incubated with the immobilized 
antigen at 37°C for 2 hours. The wells were then washed with PBS-T (0.5% Tween-
20) to eliminate non-binding phage. The number of washes was increased from five 
times with PBS-T (0.1% Tween-20) in first round of panning to 10 times in round 
two and 15 times in rounds three and four. Bound phage were eluted with 100mM 
triethylamine and used to infect E. coli XL-1 Blue cells. Super Broth (SB) medium 
(1%(w/v) MOPS, 3%(w/v) Tryptone, Difco, 2% (w/v) yeast extract, pH 7.0) was 
added into the eluted phage and XL-1 cells mixture. The culture was incubated for 1 
hour at 37°C on shaker at 200rpm. M13KO7 helper phage (100µL of 1013 pfu/mL 
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stock) was added to the 8mL culture, followed by further up-scaling of culture with 
SB broth to 100mL. The culture was incubated overnight at 37°C on shaker at 
200rpm. Input phage for the next round of panning was prepared via centrifugation of 
the 100mL culture at 3000g for 15min at 4°C (JA-14 rotor), followed by Polyethylene 
Glycol (PEG) precipitation of the phage supernatant. Precipitated phage was pelleted 
via centrifugation at 16000g for 5 min at 4°C, and resuspended in 1% BSA in PBS. 
Phage preparation could be stored at 4°C with addition of 0.02% Sodium Azide, or at 
-80°C with addition of 15% Glycerol. For input tittering, 50 µL of XL-1 Blue culture 
was infected with 1µL of 10-7, 10-8 or 10-9 dilution of the phage preparation. After 
incubation for 15 min at room temperature, each was plated on a 2xTY/AG plate, 
followed by overnight incubation at 37°C. Input titer calculation was performed by 
multiplying the number of colonies by the culture volume and dividing by the plating 
volume. 
 
2.7.2 Negative selection to eliminate His tag- and Rabbit Polyclonal Antibody-
binders from the library 
 
Prior to panning, phage library was incubated with His-tagged control protein and 
Rabbit PAb at high concentration (100µg/mL) for 2 hours at RT on a rotating wheel 
(method was adapted from Shiryaev et al.(1)). 
 
2.7.3 Polyclonal ELISA of Fab-Phage clone 
 
Maxisorb 96-well immunoplate (Nunc, USA) was coated with 100 µl/well of protein 
at 5 µg/ml concentration: EDIII, DENV-2 TSV01 whole virus, or His-tagged control 
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protein (His tagged-NS2B-NS3 pro185) in Sodium Bicarbonate buffer (pH 9.6), BSA 
or Rabbit Polyclonal Antibody in PBS (pH 7.2) overnight at 4°C and washed twice 
with PBS before blocking with 300 µl/well MT buffer (PBS supplemented with 5% 
skim milk powder and 0.1% Tween-20) at 37°C for 1 hour. 100 µl/well of diluted (1:4 
in MT buffer) PEG precipitated phage of first, second and third and fourth pans were 
added to the coated plate that was pre-washed twice with PBS. After incubation at 
37°C for 1 hour, plate was washed five times with PBS-T, and 100 µl/well diluted 
(1:5000 in MT buffer) HRP-conjugated anti-M13 MAb (GE Healthcare) was added. 
After incubation at 37°C for 1 hour, plate was washed three times with PBS-T and 
once with PBS, and 50 µl/well 3,3′,5,5′ tetramethylbenzidine (TMB; Sigma, USA) 
substrate was added. After incubating for several minutes for colour development, 
12.5 µl/well of 3M HCl was added to arrest the reaction. Absorbance was measured at 
450nm to identify PEG precipitated phage library that was positive when the signal 
was 2-fold higher than background signal. 
 
2.7.4 Small-Scale Phage Rescue 
 
XL-1 Blue-phagemid colonies were picked following the fourth round pan for small-
scale phage rescue in a 96-well plate and each was used to inoculate 500µL of 
2xTY/AG (Tryptone Yeast Broth, supplemented with 100 µg/mL ampicillin and 10 
µg/mL Tetracycline) per well. The culture was incubated overnight at 37°C in 
Thermomixer (Eppendorf) at 800rpm. 5µL of culture was added to a new plate 
containing 500µL of 2xTY/AG/ well on the following day, and the culture was 
incubated under the same condition for 3 hours (until OD~0.5). M13KO7 helper 
phage was added at MOI 20 to each well, and the plate was incubated undisturbed at 
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37°C for 30min. Following centrifugation at 4000g for 5min at 4°C, supernatant was 
removed and the cell pellets were resuspended in 500µL 2xTY/AK (Tryptone Yeast 
Broth, supplemented with 100 µg/mL Ampicilin, 50 µg/mL Kanamycin and 10 µg/mL 
Tetracycline) per well, and incubated overnight at 30°C in Thermomixer (Eppendorf) 
at 800rpm. 
 
2.7.5 Monoclonal ELISA 
 
Three separate Maxisorb 96-well immunoplate (Nunc, USA) were each coated with 
100 µl/well of EDIII, DENV-2 TSV01 whole virus, or His-tagged control protein (His 
tagged-NS2B-NS3 pro185) at 5 µg/ml concentration, incubated overnight at 4°C and 
washed twice with PBS before blocking with 300 µl/well MT buffer (PBS 
supplemented with 5% skim milk powder and 0.1% Tween-20) at 37°C for 1 hour. 
100 µl/well of diluted phage supernatant (1:4 in MT buffer) from individual clones 
were added to the coated plate that was pre-washed twice with PBS. After incubation 
at 37°C for 1 hour, plate was washed five times with PBS-T, and 100 µl/well diluted 
(1:5000 in MT buffer) HRP-conjugated anti-M13 MAb (GE Healthcare) was added. 
After incubation at 37°C for 1 hour, plate was washed three times with PBS-T and 
once with PBS, and 50 µl/well 3,3′,5,5′ tetramethylbenzidine (TMB; Sigma, USA) 
substrate was added. After incubating for several minutes for colour development, 
12.5 µl/well of 3M HCl was added to arrest the reaction. Absorbance was measured at 
450nm to identify clone(s) that bind strongly to both whole virus and EDIII, and show 
negligible binding to His-tag antigen. 
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2.7.6 Western Blot to detect binding of phage to DENV-2 TSV01 whole virus 
and EDIII protein. 
 
500ng/well of DENV-2 TSV01 whole virus or DENV-2 EDIII (boiled at 100°C for 5 
min together with β-ME-containing 4xgel loading dye) was loaded onto 12% SDS-
PAGE gel, and gel was run at 120V for 1 hour. Following transfer of proteins onto 
membrane (BioRad Wet transfer apparatus, Amersham Hybond-P PVDF transfer 
membrane), the membrane was blocked overnight in blocking buffer (PBS-T (0.1% 
Tween-20) +5% milk) at 4°C on shaker. Membrane was incubated with the respective 
phage supernatant (diluted 1:25 in blocking buffer), or 9F12 MAb (at 1:500 dilution 
in blocking buffer) as a positive control, for 2 hours at RT. Following a series of 
washing (5x in PBS-T), each membrane was incubated with HRP-conjugated anti-
M13 antibody (GE Healthcare) for phage primary antibody at 1:1000 dilution in 
blocking buffer, or HRP-conjugated anti-mouse antibody for 9F12 primary antibody 
at 1:5000 dilution in blocking buffer for 1 hour at RT. Membrane was developed 
using Amersham Biosciences ECL detection kit and analyzed on IQuant. 
 
2.8 DETERMINATION OF REPLICATION, DISSEMINATION AND 
VIREMIA TITRES OF DENV-2 EDEN AND PDK-53 STRAINS IN 
MOSQUITOES AT VARIOUS TIME-POINTS POST-INOCULATION 
 
2.8.1 Intrathoracic inoculation  
 
180 adult male Ae.Aegypti mosquitoes were separated into two groups for inoculation 
with 2 strains of DENV-2 (DENV-2 EDEN and PDK-53). The mosquitoes were 
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immobilized on ice for at least 15 minutes prior to inoculation. All the mosquitoes 
were recoded and labeled accurately using the Mosquito Experiment/ Transfer 
Record. All inoculations were performed within a biological safety cabinet during 
which they were temporarily placed within a petri dish held on ice or chill table. Glass 
needle was loaded with 0.17µL inoculum (sterile PBS containing 100 PFU of virus) 
that was injected into each mosquito directly into the underside of the neck while it 
was positioned on the dorsal aspect of its thorax. Following inoculations all 
mosquitoes were contained within a holding carton, mesh cage, and stored within an 
environmental chamber for the duration of the extrinsic incubation period. Infected 
mosquitoes were fed blood or sugar solutions (10% Sucrose, dH20) through the mesh. 
Chamber humidity (70%) and temperature (27°C) were kept constant. Disposal of 
mosquitoes was into a screw-top container with 70% Ethanol. Five mosquitoes per 
group were taken at several time points post-inoculation (D2, D4, D8, D10, D14 and 
D16) to be frozen at -80°C. 
 
 2.8.2 Comparison of viremia titres of mosquitoes at various time points post-
infection between DENV-2 EDEN and DENV-2 PDK-53 
 
Each mosquito was homogenized in 500µL RPMI-1640 (+5% FBS +1% Pen/Strep) 
using a disposable/ autoclavable pestle. Cell debris was pelleted via centrifugation 
(14000g, 2 min, 4°C). Virus-containing supernatant was serially diluted in RPMI-
1640 (+2% FBS +1% Pen/Strep) and subsequently added onto 96-well plate 
containing BHK-21 cells (seeded at 104 cells/well and incubated overnight at 37°C, 
5% CO2) after medium aspiration. The mixture was incubated at 37°C, 5% CO2, and 
plate was gently rocked every 15 minutes to ensure even adsorption. Each sample was 
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done in triplicate. 150µL maintenance medium (RPMI-1640 +2% FBS +1% 
Pen/Strep) was subsequently added and plates were incubated for 4 days at 37°C, 5% 
CO2. Cells were fixed with cold Acetone for 5 min at -20°C and washed with PBS. 
Anti-Flavivirus antibody NG2 (1 in 10 dilution in PBS) was added to each well (50 
µL/well) and incubated at 37°C for 1 hr. After washing with PBS twice, FITC-
conjugated Sheep Anti-Mouse (1 in 200 dilution in PBS) was added to each well 
(30µL/well), and incubated at 37°C for 1 hr. After washing twice with PBS, the 
fluorescence was viewed under a fluorescent microscope. The dilution factor of the 
mosquito homogenate at which last fluorescence was observed was taken for further 










































3.1 SUBJECT A- IRB APPLICATION FOR HUMAN SERUM STUDY 
 
The flow chart below outlines the procedures of the IRB (Institutional Review Board) 
application for the human serum study. The application was first drafted in May, 
followed by the interview with Subject A to obtain the detailed history of Subject A’s 
infection (Figure 5). The application was submitted in July (Appendix 2) and received 
approval from the NUS-IRB committee in August. Blood withdrawal was 
subsequently performed on Subject A to obtain serum samples used in the serum 
characterization study.  
 
May 2010: IRB application form drafted 
 
June 2010: Interview with Subject A 
 
June 2010: Review of IRB application with supervisors 
 
July 2010: Submission of IRB application 
 
August 2010: Approval  
 






Figure 5. Flavivirus infection history of Subject A 
 
 
History of Flavivirus infection 
 
1967: infection with Langat Virus (Tick Borne Encephalitis Virus) while studying in Johns 
Hopkins University. 
 
1969-1971: lived and worked in India, no Flavivirus infection. 
 
1972: Yellow Fever Virus immunization, Honolulu, Hawaii. 
 
1973: DENV2 infection acquired in Honolulu, Hawaii. 
• Confirmation: virus isolation. 
• Cause: accidental exposure to infected mosquitoes while feeding the 
mosquitoes on experimental monkeys. 
• Clinical manifestations: 
o High fever (for 6 days) 
o Muscle pain, back ache 
o Loss of appetite 
o Severe frontal headache 
o No nausea 
o No diarrhea 
o No abdominal pain 
o Morbiliform skin rash 
o No hemorrhagic manifestation 
• Did not receive any treatment or hospitalization 
 
1970’s: Indonesia. No known infection.  
 
Early 1980’s: Yellow Fever Virus immunization 
 
1981: DENV1 infection acquired in Puerto Rico 
1986: DENV4 infection acquired in Puerto Rico 
• Both occurred by natural infection during epidemic. 
• Both were confirmed by virus isolation from blood. 
• Mild manifestations (fever). 
• Did not receive any treatment or hospitalization 
 
Early 1990’s: Japanese Encephalitis Virus vaccination 
 
2003: West Nile Virus infection in USA 
• Asymptomatic. Family member (wife) had symptomatic infection (mild fever 
and visible skin rash). 
• Natural infection 






3.2 CHARACTERIZATION OF SERUM FROM SUBJECT A 
 
The first component of this project is aimed to characterize the neutralization pattern 
of the serum obtained from Subject A, who has had multiple Dengue Virus infection 
as well as exposure to several other Flavivirus infections over 40 years (Figure 5). 10 
mL of blood was obtained via venipuncture, allowed to clot and centrifuged for the 
separation of serum. The serum obtained was heat inactivated, and stored as 100µL 
aliquots at -80°C. With prime interest in investigating the role of EDIII-specific 
antibodies that are present in human convalescent serum in DENV neutralization, this 
study commenced with the preparation of purified EDIII protein and whole virus 
antigens.  
 
3.2.1 Expression and Purification of DENV-2 and -3 Ectodomain III (EDIII)  
 
The expression construct of His tag-DENV-2 EDIII protein (DENV-2 EDIII gene 
inserted into pET16bD2T plasmid with T7 promoter, sequence included in the 
appendix) (39) was transformed into at BL21 E.coli for expression of EDIII protein in 
LB with IPTG induction at 37°C for 4 hours. The EDIII proteins are insoluble so 
proteins are purified and refolded after extraction from inclusion bodies. Cells were 
harvested by centrifugation, lysed by sonication and the insoluble pellet was 
resuspended in an 8M urea buffer for purification. His-tagged EDIII was initially 
captured in the Ni-NTA column and eluted with a gradient of Imidazole (10-
1000mM) in 8M urea. The fractions that contained the eluted protein (fractions C1 to 
C11) were pooled (Figure 6, 15kDa band) for refolding by dialysis. 
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Figure 6. SDS-PAGE illustrating eluted fractions of soluble His-tagged DENV-2 EDIII 
protein captured with Ni-NTA column. MW: Precision plus protein standards (kDa), S/N: 
supernatant obtained pre-elution, FT: Flow-through from His-tagged EDIII capture by Ni-
NTA column, C1-E5: eluted fractions. 
 
 
Exhaustive dialysis was used to remove 8M urea and refold the EDIII proteins. 
Proteins were dialysed into dialysis buffer (refer to Materials and Methods), with 
regular buffer changes over 48 hours at 4 °C. Protein precipitate was removed by 
centrifugation and the refolded EDIII protein was concentrated to 1mL for final 
purification by Size Exclusion Chromatography (SEC). The clean peak in the SEC 
elution profile (data not shown) and single bands at 15kDa observed by SDS-PAGE 
gel showed that the purified protein was properly folded (Figure 7). The typical yield 
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Figure 7. SDS-PAGE illustrating eluted DENV-2 EDIII protein fractions after refolding by 
dialysis and purification by SEC. MW: Precision plus protein standards (kDa), S/N: 




3.2.2 Propagation of DENV-2 TSV01, DENV-3 H87, DENV-1, 2, 3 and 4 EDEN 
in C6/36 cell line 
 
Virus supernatants for the two DENV reference strains used in this study (DENV-2 
TSV01 and DENV-3 H87) were harvested from virus propagation in Ae. Albopictus 
derived C6/36 cells. Similarly, clinical DENV for all four serotypes were propagated 


















Plaque assays were performed to determine the virus titres, as summarized in Table 1.  
 
Table 1. Summary of the titres of the six DENV strains propagated in C3/36 cell line, 
determined by Plaque Assay. Each virus dilution and the controls were performed in triplicate 










3.2.3 Concentration, Sucrose gradient and UV-inactivation of DENV-2 TSV01 
and DENV-3 H87 
 
The whole virus antigens from the two reference strains (DENV-2 TSV01 and 
DENV-3 H87) were purified by sucrose gradient and UV-inactivated. Sucrose 
gradient allows separation of the different components in the virus supernatant based 
on shape and size. Non-aggregated whole virus particles are expected to be 
“cushioned” between the 22% and 33% Sucrose fractions. Should extensive 
aggregation occur in the concentrated virus supernatant preparation, protein bands 
would be observed across all fractions, since the aggregated whole virus particles tend 
to be of arbitrary sizes, and hence positioned at a continuous range of the sucrose 
gradient. Following layering of the sucrose gradient, 2 mL of concentrated virus 
supernatant was layered carefully on top of the topmost 11% Sucrose. After overnight 
DENV Strain Titre (pfu/mL) 
DENV-2 TSV01 4.5 x 106 
DENV-3 H87 1.2 x 106 
DENV-1 EDEN 2.3 x 106 
DENV-2 EDEN 5.7 x 107 
DENV-3 EDEN 4.0 x 106 
DENV-4 EDEN 1.4 x 107 
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ultracentrifugation, a total of 16 fractions from the gradient were collected for 
analysis. Each of these fractions were run on 12% SDS-PAGE gel. Bands at the size 









    
 
Figure 8. DENV-2 TSV01 purification by Sucrose Gradient. SDS-PAGE illustrating Sucrose 
gradient fractions; MW: Precision plus protein standards (kDa), S/N: concentrated virus 
supernatant prior to loading, 6-16: virus-containing sucrose gradient fractions. SDS-PAGE gel 




However, as FBS is present in the supernatant (with molecular weight similar to that 
of the E protein of the virus), it could not be clearly distinguished from that of E 
protein in the SDS-PAGE. Western Blot was performed, with the mouse monoclonal 
antibody 9F12 (specific for EDIII) enabling identification of the fractions that 
contained virus particles without minimal amount of FBS (Figure 9). Western blots 
for DENV-3 were performed with human monoclonal D11C antibody (specific for 
EDI and EDII of DENV E protein). 
 
    
 


















Figure 9. Western Blot with 9F12 MAb to identify sucrose gradient fractions containing 
purified DENV-2 TSV01 virus particles. MW: Precision plus protein standards (kDa), 6-13: 
virus-containing sucrose gradient fractions. Membrane was probed with 9F12 MAb and HRP-
conjugated anti-mouse antibody as the primary and secondary antibodies, respectively.  
 
 
Figure 9 shows that fractions 9 to 13 contained high amount of virus, based on the 
thickness of 55 kDa bands observed. These fractions were buffer exchanged to 
remove sucrose, and UV-inactivated. Typical yields were in the range of 7-8 mgs for 
both DENV2-TSV01 and DENV-3 H87.  
 
 
3.2.4 ELISA Optimization for Serum Characterization 
 
ELISA with well-characterized mouse MAbs was performed to optimize the assay 
conditions, ensuring proper coating of wells with the antigens (DENV-2 whole virus 
and EDIII) for subsequent serum binding experiments.  
 
After several trials, blocking conditions and the amounts of antigens used to coat each 
well for ELISA were established. Three hours of blocking at room temperature or 
overnight at 4°C with PBS containing 2% FCS, 3% (w/v) milk and 1% Tween-20 in 
resulted in minimum background ELISA signals due to non-specific binding. These 
conditions were adopted in all the subsequent serum ELISAs. The amount of whole 
virus coated on each well was titrated to determine the saturation point, i.e. the lowest 





concentration where maximum signal is observed. Coating each well with 75ng of 
virus (or 50µL/well of 1.5µg/mL whole virus) gave sufficient ELISA signals with no 
signal increase observed from coating each well with 200ng of virus (or 50µL/well of 
4.0µg/mL whole virus). Therefore, 75ng/well was determined to be the optimum 
amount for coating. 
 
Successful coating of antigens in the ELISA (whole virus and EDIII of DENV-2 and 
DENV-3) was demonstrated using MAbs 3H5 and D11C (Figures 10 and 11). The 
end-point titres for 3H5 against DENV-2 WV and EDIII were determined as 3200 and 
12800 respectively (Figure 10). 3H5 binds to the lateral ridge epitope of DENV-2 
EDIII (36, 38). The higher end-point titre for EDIII compared to WV suggests that the 
EDIII epitope that 3H5 MAb binds to is poorly exposed on the intact virus but not on 
recombinant EDIII, similar to the observations made by Wahala et al using 8A5 and 
12C1 MAbs (40). 
 
Similarly, binding of D11C MAb to the DENV-3 H87 whole virus confirmed the 
presence and availability of antigen (Figure 11) on ELISA plate after coating, with the 
end-point titre of 50 against WV. D11C Mab is cross-reactive across the four DENV 
serotype and binds to the EDI and EDII of the DENV E protein. The binding of 









Figure 10. Binding of 3H5 monoclonal antibody to DENV-2 TSV01 whole virus (red line) 
and EDIII (blue line). The end-point titre was determined as the reciprocal of the highest 
dilution that gave a signal greater than Mean+3 standard deviations of baseline (FCS was used 
as negative control). The data are one of two representative experiments. 
 
 
Figure 11. Binding of D11C monoclonal antibody to DENV-3 H87 whole virus (blue line) 
and EDIII (red line). The end-point titre was determined as the reciprocal of the highest 
dilution that gave a signal greater than Mean+3 standard deviations of baseline (FCS was used 






3.2.5    ELISA Using Serum from Subject A Against DENV-2 and DENV-3 
 
Binding of Subject A’s serum to the whole virus and EDIII of both DENV-2 TSV01 
and DENV-3 H87 demonstrated the presence of reactive antibodies to the respective 
antigens (Figure 12). The serum end-point titres are summarized in Table 2. The titre 
of reactive antibodies against DENV-2 whole virus was observed as the highest at 
32000 (Figure 12), followed by significantly lower antibody titres against DENV-3 
H87 whole virus (3200), DENV-2 EDIII (2000) and DENV-3 EDIII (800).  
 
 
Figure 12. Binding of Subject A’s serum to DENV-2 and DENV-3 whole virus and EDIII. 
The data points represent the mean values (each dilution was performed in duplicate) and the 
error bars represent the standard error of the mean. The data are representative of three 







Table 2. The titre of DENV whole virus and EDIII-reactive antibody in Subject A’s serum 





*The end-point titre was determined as the reciprocal of the highest dilution that gave a signal greater 




3.2.6 Plaque Reduction Neutralization Test (PRNT) 
 
Plaque Reduction Neutralization Test (PRNT) was performed to determine the 
neutralizing antibody titre present in Subject A’s convalescent serum against each of 
the four DENV serotypes. The different serotypes of DENV at known Plaque 
Forming Unit (PFU) per well were mixed with serially diluted serum. Upon 
incubation, this “neutralizing mix” was added onto BHK-21 cells, with the reduction 
in the infection of these cells indicating the presence of neutralizing antibodies in the 
serum. PRNT were repeated three times and a representative set of data obtained are 
summarized in Table 3 and illustrated in Figure 13a and b. The lowest titre at which 
50% reduction of the number of plaques was observed was determined to be the 50% 
neutralization titre of the serum against the respective DENV serotype. The same 





 End-point titre * 
Whole virus 32000 DENV-2 TSV01 
EDIII 2000 
Whole virus 3200 DENV-3 H87 
EDIII 800 
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Figure 13. Determination of 50% DENV neutralization titre of Subject A’s serum against the 
four DENV serotypes by PRNT. 50% neutralization titre was determined as the highest serum 
dilution in the virus+serum neutralizing mix that reduces the number of plaques by 50%. Each 
serum dilution was done in triplicate. The negative controls (Virus Control (VC)= virus + 
media) were performed in duplicate, for the quantification of the virus into each well and the 
subsequent calculations of plaque reduction and the percentage neutralization. The positive 
controls were virus + undiluted MAbs (3H5, 9F12 and 4G2). The data are one of three 
representative experiments. 
 
% Neutralization  
Strain 50 70 
DENV-2 TSV01 75 50 
DENV-3 H87 30 15 
DENV-1 EDEN 130 <10 
DENV-2 EDEN >320 240 
DENV-3 EDEN 20 15 
DENV-4 EDEN No protection (<10) 
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The highest neutralization titre was observed against DENV-2 serotype (Table 3), in 
particular EDEN-2 (70% and 50% neutralization occurred at serum dilutions of 240 
and higher than 320, respectively). However, the neutralization titre against TSV01 
was observed to be lower (70% and 50% neutralizations occurred at serum dilutions 
of 50 and 75, respectively). Low neutralization titres of serum against the DENV-3 
serotype were consistently observed in PRNT against DENV-3 H87 and DENV-3 
EDEN, with 70% and 50% neutralizations occurring at serum dilutions of 15 and 30 
for H87 and serum dilutions of 15 and 20 for EDEN3 strain, respectively (Table 3). 
The neutralization titres observed against DENV-2 and DENV-3 correlate with the 
end-point titres for the respective serotypes observed in the earlier ELISA. No 
protection was observed against DENV-4 serotype in any of the PRNT conducted. 
Relatively good neutralization was observed against DENV-1 serotype with 50% 
virus neutralization at 1 in 130 serum dilution but rapidly declined in higher serum 
dilution, demonstrated by the 70% neutralization against this serotype that required 
serum dilution lower than 1 in 10 (Table 3). The significant neutralization against 
serotype 2, and at a lower extent, serotype 1 of DENV by Subject A’s serum was 
consistent with the DENV infections that the subject has had in the past 40 years 
(refer to Figure 5 for the timeline of infection). However the lack of neutralization 
against DENV-4 serotype was surprising as this is the DENV serotype that Subject A 







3.2.7 Optimization of the serum depletion using Qiagen Ni-NTA Magnetic 
Agarose Beads 
 
To investigate the role of EDIII-specific antibodies in DENV neutralization, methods 
were developed to deplete Subject A’s serum of EDIII-binding antibodies, according 
to those adopted by Wahala et al (40). Three blocking solutions were tested in the 
optimization: 3% BSA, 3% FCS and 3%FCS+3% milk, each diluted in PBS (Figure 
14). DENV-2 EDIII proteins, diluted in each blocking solution, were loaded onto 
lanes 1, 3 and 5 (Figure 14). On lanes 2, 4 and 6, thick 15kDa band representing the 
enriched EDIII protein shows that the coating of the magnetic beads with EDIII has 
been done successfully under all the three blocking conditions. However, 3% FCS in 
PBS showed the cleanest profile among all, and therefore was selected as the blocking 








    
  
Figure 14. Optimization of blocking conditions for serum depletion. SDS-PAGE illustrating 









+ 3% milk 
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To test the antibody-binding capacity of the EDIII-coated beads, 4G2 and 9F12 MAbs 
were added (Figure 15). Both 4G2 and 9F12 MAbs are cross-reactive against all four 
serotypes, but only 9F12 binds specifically to the EDIII region of the DENV E 
protein. In these experiments EDIII protein was added in excess (Figure 15, Lane 2) 
to ensure optimum coating of the magnetic bead surface, demonstrated by unbound 
EDIII after incubation of EDIII with the resin (Figure 15, Lane 3) and hence a 
complete antibody depletion and minimal of non-specific binding. The absence of the 
band on Lane 4 indicated the washing to eliminate all the excess EDIII from the 
solution has been successfully completed. Following incubation with the MAb, the 
EDIII-coated beads were loaded onto Lane 6. As expected, the beads successfully 
captured the 9F12 MAb from the suspension, as represented by the heavy and light 
chain bands (Figure 15, Lane 6). These bands were not observed after incubation with 











Figure 15. Optimization for serum depletion: antibody-binding capacity of EDIII-
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Several attempts were made to deplete Subject A’s serum of EDIII binding antibodies 
before the correct conditions were determined. Ultimately depletion was achieved 
with 90µL beads suspension that was incubated for 1 hr at 4°C with His-tagged EDIII 
protein in excess (360 µL at 2mg/mL). Depletion with His tag control (His-tagged- 
NS2B-NS3 pro185) was achieved with the incubation of beads suspension with 200 
µL of His tag control protein at 3.52 mg/mL under the same conditions. The amount 
of EDIII- or His tag control- coated beads was sufficient to deplete 70µL neat serum 
of EDIII-specific antibodies. 
 
A depletion control was added (using His-tagged- NS2B-NS3 pro185) to confirm that 
the His tag on the His-tagged EDIII did not interfere in the serum depletion. The 
results show an absence of EDIII-specific antibodies only in the depleted serum 
sample (negligible, close-to-baseline ELISA signal against EDIII protein), hence 
indicating successful serum depletion (Figure 16). The negligible difference in the 
ELISA signal between EDIII- and the undepleted or His tag-depleted sera also 
indicates that His tag did not interfere with the depletion of EDIII-specific antibodies 
from the serum. Furthermore, the ELISA signals from all the three groups of serum 
are observed to reach the baseline level between the dilution of 1:800 and 1:3200. 
This corresponds with earlier observations where the end-point titre of the serum 
against DENV-2 EDIII was determined to be 2000 (Figure 12). The serum depletion 
and the subsequent ELISA and PRNT experiments were repeated three times with 

















Figure 16. Depletion of EDIII-reactive antibody from Subject A’s serum (a) SDS-PAGE gel 
illustrating the serum depletion procedures. (b) ELISA using the undepleted (dark grey bar), 
His tag control (black bar), and depleted (light grey bar) sera, against DENV-2 EDIII. Each 
serum dilution was performed in duplicate. The values represent the means, and the error bars 
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3.2.8 EDIII depletion and PRNT 
 
The PRNT result against DENV-2 TSV01 using Subject A’s serum (Figure 17) 
indicated that there was no significant reduction in the 50% neutralization titre of the 
serum after it was depleted of the EDIII-specific antibodies. A significant reduction in 
the neutralization capacity of serum post-depletion would have been observed as a left 
shift of the depleted serum curve (Figure 17, blue). This negligible change in the 
neutralizing capacity of convalescent serum post-depletion is similar to those 










    
Figure 17. Depletion of EDIII-reactive antibody from Subject A’s serum: PRNT. Data 
illustrates percentage neutralization of DENV-2 TSV01 by depleted (blue) and undepleted 
(red) sera at various dilutions. His tag-depleted serum was used as control (green). Each serum 
dilution was performed in triplicate. Data represent the means, and the error bars represent 






Log10 (1/serum dilution) 
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3.3 SUBJECT A INFECTION STUDY 
 
The characterization (ELISA and PRNT) results of Subject A’s serum have indicated 
a protective immunity to DENV-2. The mosquito bite experiment for which IRB 
approval was granted (Appendix 2) was aimed to test the hypothesis that an elevation 
in the highly neutralizing EDIII- reactive antibody may be observed upon re-exposure 
of subject to the same serotype. 
  
 
3.3.1 Optimization for mosquito infection 
 
Immobilization (on ice) of male Ae.aegypti mosquitoes 
 
Intrathoracic inoculation with 100 PFU of 
DENV-2 EDEN or DENV-2 PDK-53  
 
Maintenance of mosquitoes in environmental chamber 
 
Mosquitoes frozen at several time points post-inoculation to compare viremia and 
replication of each strain at the respective time point 
 
Homogenization of mosquitoes 
 
Infection of BHK-21 cell line with serially diluted homogenates 
 




The flow chart outlines the optimization process of mosquito inoculation.  Following 
five days incubation post-infection with mosquito homogenate, BHK-21 cells were 
fixed and stained with NG2 (anti-flavivirus) antibody and FITC-conjugated sheep 
anti-mouse antibody.  
 
 
Figure 18. Infection of BHK-21 cell line using the homogenate of infected Ae.aegypti, 
detected by Immunofluorescence. Three mosquitoes from each time point post-inoculation 
were homogenized, and each homogenate dilution was performed in triplicate. The values 
represent the means of highest dilution factors at which fluorescence was observed, and the 
error bars represent the standard deviations. RPMI 1640 was used as negative control and did 
not show any fluorescence. Neat virus stocks were used as positive controls.   
 
 
Figure 18 demonstrated the significant reduction in the ability of DENV-2 PDK-53 
(vaccine strain) to propagate in the mosquito, in comparison to that of DENV-2 
EDEN. This is shown by a greater than 1 (close to 2) log reduction in endpoint 
dilution (a measure of viral replication) for the vaccine strain compared with the 
clinical strain over the 14 day experiment. This confirms earlier observations by Khin 
et al. (46) that the vaccine strain (DENV-2 PDK-53) is unable to propagate well in 
mosquitoes infected via oral route. Moreover, Khin et al’s observations also showed 
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the diminished replication (100x lower compared to wild type strain) and 
dissemination of vaccine strain (PDK-53) virus to the brain and salivary gland tissues 
via oral infection, resulting in no transmission (46).  
 
This observation, combined with delays in the establishment of the insectary and 
mosquito-breeding facilities represented significant roadblocks in continuing with the 
mosquito bite experiment. This was further hampered by an extensive traveling 
schedule of Subject A, and the safety of Subject A due to the observed low titre of 
DENV neutralizing antibody in his serum. The next step had been to study Subject 
A’s serum characteristics following a DENV-2 infection via a mosquito bite (to 
mimic the natural route of infection). However, for the reasons outlined above, this 
aspect of the project was no longer investigated, ad focus was instead placed on 




3.4 PHAGE DISPLAY IMMUNE LIBRARY 
 
3.4.1 The Chimeric Mouse/ Human EDIII Phage Library 
 
A chimeric human/ mouse EDIII phage library was previously constructed in the 
Vasudevan Laboratory by Dr. Nicole Moreland (Figure 19).  
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Figure 19. Generation of hybridoma and construction of the chimeric human/mouse EDIII 
phage library: Immunization of Balb/c mice with DENV-2 EDIII for the generation of 
hybridomas, followed by the mRNA extractions and pooling from the selected hybridomas, 




Ten hybridomas made following immunization of Balb/c mice with DENV2 TSV01 
EDIII were used as template in the library construction. This includes 9F12, a well-
characterized cross-reactive EDIII MAb (39). The amplification of all the Variable 
Light (VL) and the Variable Heavy (VH) chain genes was achieved with a set of 43 
primers via PCR. Following the amplification of human constant light (Cκ) and 
human constant heavy (CH1) chain gene, the mouse VL was combined with the human 
Cκ to form a chimeric light chain, whereas the mouse VH was combined with human 
CH1 to form a chimeric heavy chain. An overlap PCR was then performed to combine 
the chimeric light and heavy chains that were subsequently ligated into a pComb3X 
vector. Previous biopanning experiments conducted by Dr. Moreland had been 
unsuccessful. Four rounds of biopanning against DENV-2 TSV01 WV immobilized 
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by direct coating on a Nunc 96-well immunoplate identified only non-specific clones. 
When three rounds of biopanning were performed against EDIII, a large proportion of 
the EDIII binders that did not bind WV were obtained as a result.  
 
It was thought that the capture of whole virus antigen by direct coating may have 
partially denatured the virus particle and affected the availability of important 
epitopes. In this study an antigen capture method on the WV was explored (as 
illustrated in the figure below) to ensure abundance of the antigen and the availability 










3.4.2 Optimization of biopanning using whole virus  
 
Optimizations were performed using a Rabbit Polyclonal anti-DENV Antibody to 
capture WV antigen, and to determine the optimum concentration of WV for coating. 
WV at two concentrations (40 and 60 µg/mL) were captured by immobilized Rabbit 
PAb, and it was observed that at higher dilutions of 3H5 MAb and the secondary 







obtained (Figure 20). The result demonstrates successful capture of WV antigen by 
the Rabbit Polyclonal Antibody for biopanning. Additionally, the availability of the 
EDIII epitopes on the DENV-2 WV for phage binding was also demonstrated by the 
binding of 3H5 MAb that bind specifically to the lateral ridge epitope of DENV-2 
EDIII (36, 38). Therefore the optimum concentration of whole virus antigen was 
therefore determined to be 40 µg/mL, and the final conditions for capture ELISA were 
set as incubation of 5µg/mL Rabbit PAb with 40 µg/mL WV for 2 hours at 37°C. 
 
  
Figure 20. Binding of 3H5 MAb to the captured DENV-2 TSV01 whole virus by 
Rabbit PAb. The data are presented in fold increase of absorbance (OD 450nm) in 











3.4.3 The Three Strategies Employed in Bio-Panning 
 










Strategy I consists of consecutive rounds of biopanning against alternate antigens 
(captured WV and direct coated EDIII) to increase the stringency of selection and 
enrichment of strong WV/EDIII binders in the library. In Strategy II, phage from Pan 
I of Strategy I were subject to a series of biopanning against WV. A negative selection 
with His tag control protein and Rabbit PAb was also performed to eliminate the His 
tag and Rab PAb binders from the library. Finally, in Strategy III phage from Pan II 
of Strategy II were subject to further biopanning against EDIII.  
 
 
3.4.4 Biopanning: STRATEGY I 
 
In strategy I, captured WV and direct coated EDIII were used in consecutive rounds 




P1 P2 P3 P4 
WV EDIII WV EDIII 
 Strategy 1 
 






Negative selection with His-tag and  






summarized in Table 4. A significant reduction in the output % was observed after the 
second round of biopannning (selection of WV binders against EDIII). However, in 
the subsequent round of panning, it steadily increased with the final output % after the 
4th round of panning at 2.3 x 10-5 compared to 4.7 x 10-7 after the 2nd round of 
panning. An increase in output titre may suggest an enrichment of binders throughout 
the selection process (47). 
 
Table 4. Summary of the input and output phage in Strategy I Biopanning 
 Round 1 Round 2 Round 3 Round 4 (END) 
Antigen conc Rabbit PAb 5 
µg/mL 
WV 40 µg/mL 
DENV-2 EDIII  
20 µg/mL 
Rabbit PAb 5 
µg/mL 
WV 40 µg/mL 
DENV-2 EDIII  
20 µg/mL 
Washes 10 10 10 15 
Input phage 2x 1012 1.7x 1012 5.28 x 1012 2.2 x 1012 
Output 
phage 
1.15 x 106 < 8000 1.9 x 106 5 x 105 
Output % 5.75x10-5 4.7 x 10-7 3.6 x 10-5 2.3 x 10-5 
 
 
A polyclonal ELISA (Figure 21) performed on the phage produced after each round 
of biopanning showed signals against WV and EDIII (represented by orange and 
purple bars, respectively) that increased gradually from the second round of panning 
(P2). However, the proportion of His tag binders was also observed to increase in a 
similar fashion, suggesting a high proportion of His-tag binders were also present. 
The unusually high ELISA signal against WV in P1 could be due to the viscous 




Figure 21. Polyclonal ELISA (Strategy I): binding of Fab-phage library to WV, EDIII, BSA, 
His tag control and Rab PAb after each round of biopanning. Each of the samples was done in 






Following this observation, 192 clones were selected for a phage rescue (a small-scale 
preparation of phage supernatants) and monoclonal ELISA. Negative results were 
obtained in that none of the clones had positive signals for both WV and EDIII. 
Although a high number of EDIII binders were present, none of them bound WV and 
many were positive for the His tag.   
 
 
3.4.5 Biopanning: STRATEGY II 
 
In the second strategy, a step of negative selection was included in the biopanning (1) 
to eliminate the His tag and Rabbit Polyclonal Antibody binders that were present in 
relatively high proportions in the first panning strategy. Another approach employed 
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in the second strategy was using captured WV across the series of biopannning to 
further enrich the strong WV binders in the library. The negative selection was 
successful in eliminating the His tag and Rabbit PAb binders from the library, as 
shown by the diminished signals against His-tag and Rabbit PAb in P3 input in 
comparison to P4 input (Figure 22). However, the diminished signal from the 
polyclonal ELISA against EDIII (Figure 22, P4 (WV capture panning)) suggests that 
most of the EDIII binders were also eliminated together with the His tag binders, 













Figure 22. Polyclonal ELISA (Strategies II and III): binding of Fab-phage library to WV, 
EDIII, BSA, His tag control and Rab PAb after each round of biopanning. Each of the samples 
was done in duplicate. The data represent the mean absorbance values, and the error bars 









3.4.6 Biopanning: STRATEGY III- Identification of WV binders and a 
WV/EDIII binder 
 
The final strategy was to negatively select against His tag and Rabbit PAb binders 
from the P3 input library and to pan it against EDIII (instead of WV) to enrich for the 
remaining EDIII binders, predicted to be present in small numbers. The polyclonal 
ELISA with phage from this strategy (Figure 22, P4 (EDIII panning)) demonstrated 
successful enrichment of strong EDIII binders. Additionally, an increase in the 
proportion of WV binders suggested clone(s) with strong affinity to both WV and 
EDIII may be present in the enriched phage pool. A much lower polyclonal ELISA 
signal against His tag indicates successful negative selection. Subsequently, 192 
clones from Strategy III were selected for a phage rescue (a small-scale preparation of 
phage supernatants) and monoclonal ELISA. Two clones, D10 and H6 were shown to 
be significantly strong WV binders, with weak affinity to EDIII (Figure 23a) and 
another clone, C9, as a very strong binder to EDIII (and no binding to His tag) as 






























Figure 23. Monoclonal ELISA (Biopanning Strategy III). (a) The absorbance values obtained 
from Fab-phage clones H6, D10 and C9 against WV, EDIII and His tag. The values 
corresponds to the binding strength to each of the antigens. (b) A monoclonal ELISA layout. 
Values represent the absorbance at 450nm, and highlighted in blue are the strong binders of 
the corresponding antigen. 
 
 
EDIII 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0851 0.0981 0.1272 0.0846 0.1356 0.1349 0.0821 0.311 0.0978 0.1406 0.1174 0.097
B 1.6573 0.2115 0.1149 0.3078 0.0933 0.1002 0.229 0.1387 0.1604 0.1196 0.1836 0.0868
C 0.1236 0.1173 0.1128 0.1901 0.1742 0.1837 0.0938 0.1343 0.2827 0.092 0.1375 0.1162
D 0.1188 0.1329 0.145 0.0967 0.0948 0.1505 0.1307 0.1025 0.1395 0.1047 1.226 0.0774
E 0.1408 0.3728 0.1773 1.5844 0.1377 0.1693 0.1437 0.1121 0.0957 0.0981 0.1631 0.111
F 0.1293 0.1226 0.2098 0.1589 0.0995 0.2049 0.1248 0.0971 0.1438 0.0961 1.7262 0.1033
G 0.1387 0.108 0.1863 0.1707 0.2074 0.1037 0.3476 0.1573 0.2218 0.109 0.2225 0.1168
H 0.129 0.1177 0.1588 0.132 0.1283 0.1239 0.1174 0.1025 0.1143 0.1029 0.1189 0.1214
Whole Virus 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0941 0.0897 0.1269 0.0767 0.2393 0.0921 0.3204 0.1381 0.102 0.1329 0.1168 0.1091
B 0.1002 0.1395 0.1393 0.161 0.1012 0.1039 0.1572 0.1168 0.133 0.158 0.1336 0.1163
C 0.1361 0.1293 0.134 0.2271 0.2222 0.1393 0.1278 0.1246 0.1475 0.1584 0.1518 0.1033
D 0.1262 0.1399 0.1398 0.1158 0.1189 0.1349 0.1616 0.1443 0.118 0.7035 0.1503 0.1255
E 0.1379 0.2644 0.1665 0.1365 0.1831 0.1425 0.1681 0.1344 0.2754 0.1938 0.1379 0.1438
F 0.1394 0.1273 0.1695 0.1374 0.1172 0.4053 0.1474 0.141 0.1275 0.2188 0.1363 0.1338
G 0.1469 0.1234 0.1561 0.1335 0.151 0.1361 0.1322 0.1644 0.1683 0.166 0.1479 0.1191
H 0.1284 0.128 0.1276 0.1216 0.1205 0.5811 0.1237 0.1409 0.1239 0.1126 0.1388 0.41
His-tag 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0977 0.1114 0.1011 0.093 0.0978 0.1094 0.0916 0.1115 0.106 0.0961 0.1069 0.1017
B 0.1002 0.1314 0.094 0.1439 0.0972 0.0972 0.1743 0.1006 0.1427 0.1305 0.1907 0.0886
C 0.1286 0.1016 0.1281 0.1134 0.2073 0.1107 0.0994 0.1015 0.1865 0.0972 0.1144 0.1035
D 0.1165 0.1655 0.1186 0.1052 0.1028 0.1065 0.1057 0.1181 0.1095 0.1183 0.1039 0.104
E 0.1438 0.2567 0.154 0.1161 0.1791 0.1274 0.1102 0.112 0.1058 0.1095 0.1247 0.1575
F 0.1335 0.1264 0.1384 0.1285 0.1062 0.2202 0.1175 0.1087 0.1161 0.1065 0.1171 0.1334
G 0.1461 0.1159 0.133 0.1247 0.1813 0.1122 0.1119 0.1195 0.1726 0.1171 0.1549 0.1082
H 0.112 0.1205 0.1121 0.1174 0.1235 0.1231 0.1227 0.111 0.1138 0.1121 0.1276 0.1288
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Following the observation made on clones C9 (EDIII and WV binder and non- His tag 
binder), H6 and D10 (very strong WV binders), Western Blot using the phage 
supernatant of these clones was performed to confirm their binding specificity. The 
DENV-2 WV or EDIII protein transferred to the nitrocellulose membrane was probed 
with the phage supernatant as the primary antibody. HRP-conjugated anti-M13 
monoclonal antibody as secondary antibody reacts with the bacteriophage major coat 
protein gp8, enabling detection of phage that binds to the WV and/or EDIII protein on 
the nitrocellulose membrane. 9F12 MAb was used as the positive control. It is a well-
characterized antibody that binds to the EDIII domain of the DENV envelope protein 
and cross-reacts with all the four DENV serotypes. It detected both WV and EDIII in 
the western blot (Figure 24), as shown by the bands at approximately 55kDa and 
15kDa for the WV and EDIII lane, respectively.  
 
Western Blot with phage supernatant from clones H6 and D10 resulted in a thick band 
(approximately 55kDa) on the WV lane, and a lower detection of EDIII, indicating 
that clones H6 and D10 are strong WV binders but weak EDIII binders, confirming 
the results obtained earlier in the monoclonal ELISA (Figure 21b). Clone D10 
strongly detected EDIII and only weakly detected WV (Figure 22). Again, this was in 

















Figure 24. Western Blot to show the binding of isolated Fab phage clones H6, D10 and C9 to 
DENV-2 whole virus and EDIII. Positive control: 9F12 MAb (demonstrates binding to both 
WV and EDIII, shown by bands at 55 and 15 kDa respectively). The data are one of two 




Phagemids from the three isolated clones were subject to DNA sequencing of both 
their heavy and light chains. The results, summarized in Table 5, shows that Fab from 
clones H6 and D10 are not unique from each other, as they belong to the same heavy 
and light gene families, and bear the identical sequence in their CDR3 region. Fab 
from clone C9, however, bears unique CDR3 sequence on its heavy chain gene while 
the CDR3 sequence on its light chain however bears similarities with that of H6 and 
D10. Alignment of both the heavy and light chains of D10 and H6 showed that they 
bear the same framework sequence, and are identical in all the CDR sequences (data 
not shown), indicating that they are identical. This result agrees with those obtained 
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Table 5. Sequence analysis and variable gene usage of anti-DENV-2 EDIII Fab. Shown are the 
complementary determining region 3 (CDR3) and variable gene family designations, assigned using 
IMGT/V-Quest (http://imgt.cines.fr/). 
Fab Clone CDR3 VL VL family CDR3 VH VH family 
DENV-2     
H6 FQGSHVPYT Vκ1 ARGSDANYAYSFGVDY VH5 
D10 FQGSHVPYT Vκ1 ARGSDANYAYSFGVDY VH5 





3.5.1 Serum Characterization 
 
In this study, we aimed to characterize the neutralization profile of serum from 
Subject A, who had a history of multiple DENV and other Flavivirus infections. The 
timeline of each infection is summarized in the Subject A’s History of Flavivirus 
Infection (Figure 5), and the infecting DENV strain was verified by virus isolation 
from the subject’s peripheral blood during the period of illness. The ELISA and 
PRNT results obtained from this study both show high tires of DENV-2 reactive and 
neutralizing antibodies, compared to the neutralizing antibody titre against the other 
three serotypes. The high neutralization titre against DENV-2 observed in the PRNT 
results was expected, considering the Subject A’s exposure to this serotype a few 
decades ago. The infection with this serotype was his first recorded DENV infection, 
and among the three DENV infections the subject has been exposed to by far, the 
infection by DENV-2 resulted in the most severe manifestations.  
 
Infection with one DENV serotype results in homotypic protection, or immunity that 
protects only against that particular phenotype. Part of the protection is conferred by 
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the neutralizing antibodies, together with other components of the immune responses 
against DENV virus such as the memory T lymphocytes that are specific for DENV.  
The production of these antibodies against the serotype the subject has been infected 
with is sustained as a result of the memory B cell pool maintenance through 
homeostatic proliferation (48). Therefore, it would be expected that after previous 
infections with Serotypes 1, 2 and 4 DENV, Subject A would develop a lifelong 
immunity against all the three serotypes, and Subject A’s serum to contain 
neutralizing antibodies against them. The observed low titre of DENV-3-reactive 
antibodies in Subject A’s serum as detected by ELISA, in addition to the almost 
negligible neutralizing titre against DENV-3 as detected by PRNT are in agreement 
with the absence of DENV-3 infection during his lifetime. Interestingly, a low 
neutralization titre against DENV-1 and no protection against DENV-4 (titre <10) 
was observed although Subject A was infected with these two serotypes much more 
recently. One possible explanation could be the limited seroconversion upon exposure 
to DENV-1 and DENV-4, possibly due to neutralization by cross-protective 
antibodies that were originally generated from the earlier infection by DENV-2 and 
were still sustained in the circulation. Furthermore, it is known that the newly 
generated and old antibody-producing plasma cells compete for limited numbers of 
survival niches as part of the homeostatic mechanism (49). This may also explain the 
low quantity or absence of DENV-1 and DENV-4 neutralizing antibodies in Subject 
A’s serum if only limited seroconversion for DENV-1 and DENV-4- specific, 
neutralizing antibodies occurred during the period of infection.  
 
Studies with mouse MAbs have led to the identification and mapping of serotype-
specific epitope on the lateral ridge of EDIII in DENV (36, 38, 50) and it is believed 
 81 
that antibodies directed to this epitope play a role in serotype-specific neutralization. 
To investigate the role of EDIII-specific antibodies in the neutralization of DENV-2 
infection, Subject A’s serum was depleted of EDIII binding antibodies using EDIII-
coated resin. The PRNT results using depleted and undepleted sera from Subject A 
showed no significant reduction in the 50% neutralization titre after serum was 
depleted of EDIII-specific antibodies, confirming the previously published results 
(40). The previous EDIII depletion study concluded that the EDIII-specific antibodies 
play only a minor role in neutralization compared with EDI- and EDII-specific 
antibodies that are believed to be present in higher abundance. However, a more 
recent study by Beltramello et al (28) showed that EDIII- specific MAbs generated 
from DENV patients’ immortalized memory B cells potently neutralized DENV 
infection in vitro. Their study suggested that although EDIII-specific antibodies may 
be the minority in the antibody repertoire in human compared to the EDI- and EDII- 
specific antibodies, they are highly neutralizing (28). In keeping with this, a low 
baseline titre of DENV-2 EDIII-reactive antibodies was observed in Subject A’s 
convalescent serum as detected by ELISA. This may explain the negligible reduction 
in the neutralization observed upon depletion of Subject A’s serum.  
 
Further investigation is required to determine the exact role of EDIII-specific 
antibodies in the virus neutralization and protection. This study, and the studies by 
Wahala and Beltramello (28, 40) were conducted with convalescent serum. It may be 
that higher numbers of serotype-specific EDIII MAbs are observed in acute serum. It 
is known that the number of plasma cells peak in the peripheral blood approximately 
7 days post-infection to more than 100 times its baseline level, resulting in a sharp 
elevation in the serum antibodies. A plateau is usually reached by day 10 post-
 82 
infection, indicating a short-lived nature of the plasma cells generated (51, 52). The 
highly neutralizing EDIII-specific antibodies may be present in lower abundance in 
human repertoire but are rapidly expanded and highly boosted shortly or within a 
narrow time window upon re-infection with the same serotype. 
 
3.5.2 Phage Display Immune Library 
 
The objective of this part of the study was to isolate EDIII-reactive antibodies that are 
highly neutralizing against DENV-2 by Phage Display Technology. This method of 
antibody generation is an alternative to the conventional hybridoma technology, to 
select for high-affinity antibodies that are specific for the target protein. The Chimeric 
Human/Mouse EDIII Phage Library was generated from 10 EDIII-specific 
hybridomas, containing mouse variable chain region and human constant region on 
both of the Heavy and Light chains.  
 
During the biopanning process, many Fab-phage clones that were strong EDIII-
binders but also His tag binders, were identified. The hybridomas from which the 
library was generated were raised against His-tagged EDIII, and it seems the His tag 
was highly immunogenic in this context. The negative selection with Rabbit PAb and 
a His tag control protein successfully depleted His tag and Rabbit PAb binders from 
the library for the subsequent round of biopanning.  
 
Interestingly two clones were isolated that bound strongly to DENV-2 whole virus 
and were weak EDIII binders (negative by ELISA, weakly positive for EDIII by 
Western Blot), H6 and D10. As the library was originally generated upon inoculation 
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of mice with DENV-2 EDIII antigen, these clones may either bind an epitope on 
EDIII that is wholly available on the WV particle, or errors introduced by PCR during 
the phage library generation that enabled the antibody specificity to be altered. D10 
and H6 were found to share identical CDR3 sequence. As CDR3 is the key 
determinant of specificity in antigen recognition/ binding (53), this implies that C6 
and H10 likely bind to the same epitope on EDIII. In addition, sequence alignments of 
the heavy and light chains of D10 and H6 revealed that they share identical sequences 
of both heavy and light chains, further confirming their homologous identity and 
hence binding specificity. The third clone (C9) bears a unique, markedly shorter 
CDR3 region, reflecting its different binding specificity compared with H6 and D10. 
C9 binds EDIII strongly and WV weakly in ELISA, suggesting it may bind to an 
epitope on EDIII that is not totally available on the WV particle.  
 
These clones will require further characterization before their usefulness as anti-
DENV antibodies can be assessed. The Fab should be converted to IgG and expressed 
in HEK 293T cells for neutralization studies against DENV1-4. IgG from C9 that 
binds WV and EDIII can potentially be a valuable tool for studying the mechanisms 
of viral adsorption and attachment, as well as the characterization of the binding 
specificity of the Fabs to different epitopes of EDIII. The antibodies that bind WV 




In this study, we have performed serum characterization of Subject A who had a 
history of multiple Flavivirus infections in the past 40 years and investigated the role 
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of EDIII-specific antibodies in DENV neutralization. The absence of reduction in 
neutralizing capacity of serum that was depleted of EDIII-specific antibodies may 
suggest the minor role of EDIII in neutralization and protection. However it was 
hypothesized that a significant elevation in the levels of highly neutralizing EDIII-
specific antibodies in the serum may occur within a narrow time window upon re-
infection. Finally, two unique Fab clones with specificity for epitopes on EDIII and 
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Title:         Position:       
*The Head of Department can be the Head / Chief of the PI’s Department.  
If the PI or co-investigators is the Head or Chief of PI’s Department, this section should be completed by the Vice-




** IMPORTANT - Please complete Section V and VI, only if your existing 
research protocol submitted do not contain the relevant sections. 
 
V. ABSTRACT OF RESEARCH PROPOSAL 
In no more than 300 words, describe concisely the specific aims, hypotheses, 
methodology and approach of the application, indicating where appropriate the 
application’s importance to science or medicine.  The abstract must be self-
contained so that it can serve as a succinct and accurate description of the 
application when separated from it. Please use lay terms. If this not possible, the 




Dengue Virus (DENV) is known as the causative agent of Dengue Fever and Dengue 
Hemorrhagic Fever/ Dengue Shock Syndrome (DHF/DSS). Infection with one of the 
DENV serotypes (DENV-1, 2, 3 or 4) can elicit homotypic protection but infection with 
heterologous serotype enhances the risk for DHF/DSS development, through a 
mechanism known as Antibody Dependent Enhancement (ADE), where cross reactive 
but non-neutralizing antibodies form immune complexes that enhance virus 
internalization and replication. The DENV Envelope (E) protein has been shown to be 
the primary target for antibodies that neutralize the infection, and in this study, we aim to 
characterize the binding specificity of human DENV serum from a DENV-2-immune 
subject, and to identify strongly neutralizing human monoclonal antibodies using phage 
display. A subject with a verifiable immunity to DENV-2 will be challenged with EDEN-
2 strain. A potential boost in the DENV-2-specific antibodies will be investigated using 
subject’s serum samples that will be collected on several days post-infection. Findings 
from this study will lead to a better understanding on the antibody repertoire and 
distribution following re-exposure to antigen (DENV), as well as the role of the EDIII 
(Ectodomain III, as part of the Envelope protein)-specific antibodies in the 





VI. PROTOCOL CHECKLIST 
Organise details of the research protocol under the following headings (in no more than 
7 pages). 
1. Specific Aims: 
1.1 State concisely and realistically what the research described in this application is intended to 
accomplish and/or what hypothesis is to be tested. 
 
- To characterize the binding specificity of human DENV serum from a DENV-2-
immune subject, and  
- To identify strongly neutralizing human monoclonal antibodies using phage display. 
 
2. Introduction: 
2.1 Briefly describe the background to the current proposal. 
 
Dengue Virus (DENV) is known as the causative agent of Dengue Fever and Dengue 
Hemorrhagic Fever/ Dengue Shock Syndrome (DHF/DSS). Infection with one of the 
DENV serotypes (DENV-1, 2, 3 or 4) can elicit homotypic protection against the 
serotype that caused the initial infection in the long term. However, during subsequent 
infection with a different serotype of DENV, an individual may be at a greater risk of 
developing DHF/DSS through a mechanism known as Antibody Dependent 
Enhancement (ADE), where cross reactive but non-neutralizing antibodies enhances 
uptake of virus-antibody immune complex by Fcγ receptor-bearing cells, hence 
increasing productive infection. For neutralization to occur, the affinity of the antibody 
to the epitopes on the surface of the virus and its concentration need to be sufficiently 
high. 
 
The E protein has been shown to be the primary target for neutralizing antibodies 
through the blocking of the site of attachment between the virus and the host cell. The 
important roles of Ectodomain III (EDIII, one of the β-barrel structural components 
of E protein monomer) in virus attachment has also been suggested by the distal 
projection of EDIII from the virion surface, numbers of mutations that impact 
virulence or tropism map to EDIII, and the effective blocking of DENV-2 entry into 
C6/36 by recombinant WNV-EDIII in earlier studies. 
 
Presently, much of the research to elucidate the role of EDIII-reactive antibodies in 
virus neutralization has been performed with EDIII-specific mouse monoclonal 
antibodies (MAbs). The strongly neutralizing mouse MAbs have been identified to be 
serotype-specific and bind to epitopes on EDIII that are unique to each serotype, 
further suggesting the important role in EDIII in virus neutralization. Nevertheless, 
much less has been done using human immune sera to study the interactions between 
DENV and antibody, in terms of its binding, domain specificities and neutralizing 
properties. 
 
We aim to characterize the binding specificity of human DENV serum from a DENV-
immune subject and to generate an antibody phage display library in order to identify 
the strongly neutralizing human monoclonal antibodies. Findings from this study will 
lead to a better understanding on the antibody repertoire and distribution following re-
exposure to antigen (DENV), as well as the role of the EDIII-specific antibodies in the 
neutralization of DENV infection.  
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2.2 State concisely the importance of the research described in this application. 
 
In this study, we aim to characterize the binding specificity of human serum from a DENV-
immune subject upon challenge and to generate an antibody phage display library for the 
identification of strongly neutralizing human monoclonal antibodies. Findings from this study 
will lead to a better understanding on the antibody repertoire and distribution following re-
exposure to antigen (DENV), as well as the role of the EDIII-specific antibodies in the 
neutralization of DENV infection, which can be applied in future therapeutic application. 
 
2.3 Relevant references  
 
CRILL, W. & ROEHRIG, J. (2001) Monoclonal Antibodies That Bind to Domain III of Dengue Virus 
E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells. Journal of 
Virology, 75, 7769–7773. 
GROMOWSKI, G. & BARRETT, A. D. T. (2007) Characterization of an antigenic site that contains a 
dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) 
of dengue 2 virus. Virology 366, 349–360. 
OLIPHANT, T. & DIAMOND, M. S. (2007) The molecular basis of antibody mediated neutralization 
of West Nile virus. Expert Opin. Biol. Ther., 7, 885-892. 
SUKUPOLVI-PETTY, S., AUSTIN, S. K., PURTHA, W. E., OLIPHANT, T., NYBAKKEN, G. E., 
SCHLESINGER, J. J., JOHN T. ROEHRIG, J. T., GROMOWSKI, G. D., BARRETT, A. D., 
FREMONT, D. H. & DIAMOND, M. S. (2007) Type- and Subcomplex-Specific Neutralizing 
Antibodies against Domain III of Dengue Virus Type 2 Envelope Protein Recognize Adjacent 
Epitopes . Journal of Virology, 81, 12816–12826. 
WAHALA, W. M. P. B., KRAUS, A. A., HAYMORE, L. B., ACCAVITTI-LOPER, M. A. & SILVA, 
A. M. D. (2009) Dengue virus neutralization by human immune sera: Role of envelope protein 
domain III-reactive antibody. Virology 392, 103–113. 
 
3. Preliminary Studies / Progress Reports: 
3.1 Laboratory Tests  
 
Plaque Reduction Neutralization Test (PRNT) 
 
BHK-21 cells were seeded and cultured in 24-well plates until 90-95% confluent monolayer was 
formed. Preparation of virus/ serum mix (serially diluted sera + 40 PFU/well of DENV-2 
virus, incubated for 1 hr at 37°C, 5% CO2) was then added to each well. Dilutions made for 
virus controls (VC40 and VC10) were included. Following aspiration of the neutralizing 
mixture, a nutrient overlay medium (0.8% CMC) was added to each well, and the plates were 








ELISA plate was coated with 75ng/well of purified, UV-inactivated DENV-2 whole virus or 
0.1 mg/well of EDIII in 50mM Bicarbonate buffer (pH 9.6) overnight at 4°C. Following 
blocking with PBS-T (1% Tween-20 (vol/vol)) + 5% milk (wt/vol) + 2% FCS for 1 hr at room 
temperature, washing with PBS-T, the plates will be incubated for 1 hr at room temperature 
with sera. After five times of washing with PBS-T, the plates will be incubated with the 
secondary antibody (anti-human-HRP conjugated) for 1 hr at room temperature, and washed 
 100 
three times with PBS-T. 50 µL of TMB substrate will then be added to each well and the 
reaction allowed to develop for a few minutes until blue colour appears. The reaction will then 
be arrested with 3M HCl and the absorbance will be measured at 450 nm on a 
spectrophotometer. 
 
Result:   
End-point titre of Prof. Duane J. Gubler’s convalescent serum against 
DENV-2: 1 in 15849 
DENV-2 EDIII: 1 in 200 
 
4. Methodology: 
4.1 Discuss in detail the experimental design and procedures to be used to accomplish the 
specific aims of the research.  
 
Blood collection and selection of participating subject 
 
The sera used in the proposed experiments and the library generation will be obtained 
from a subject with known verifiable infection history with dengue. 
 
30 mL of venous blood will be collected in vacuum tubes by a phlebotomist to 
minimize the risk of pain or bruising at the site of blood withdrawal. The sample from 
this first collection will be the source of the convalescent DENV immune serum. With 
approval from the IRB, one participating subject will be infected with DENV-2 using 
laboratory-infected mosquitoes and another blood collection will be performed to 
obtain the “boosted” sera (0, 3, 5, 7, 10, 12 and 14 days post-infection). 
 
Approximately 20mL of blood will be collected in vacuum tubes containing sodium 
heparin to prevent clotting and then processed for isolation of PBMC using Ficoll-
Paque PLUS. The layer containing PBMC is aspirated and collected in a tube. This is 
followed by centrifugation and resuspension of cell pellets in RPMI-1640 (+10%FCS) 
medium. Using aseptic techniques, the number of cells is counted using Trypan Blue. 
For freezing, the cell pellet is resuspended in 10% DMSO in FCS (at concentration of 
2x107 cells/mL). For prolonged storage, the samples are stored in liquid Nitrogen.  
 
Serum will be obtained from 10mL of blood collected in another set of tubes 
containing clotting agent to allow subsequent clotting and collection of serum. The 
blood is allowed to clot at room temperature for 30 minutes, centrifuged and heat 




EDIII (from DENV-2 TSV01) used in this procedure is produced via IPTG-induced 
expression in E.coli, followed by sonication of pellets for lysis, His-tagged protein 
capture using Ni column, elution of protein using AKTA, and finally the rapid 
refolding of eluted protein by dialysis with protocol that has been developed in our lab. 
The protein is then run through a gel filtration column. The concentrated protein is 
stored at -80°C. Unlike in the studies done previously by Wahala et al, The DENV-2 
EDIII used in our study is not expressed as a MBP fusion protein, to ensure correct 




Whole DENV-2 virus is the other antigen used in these studies. Plaque assay using 
BHK21 cell line was performed to determine the virus titre, after propagation in 
C6/36 cell lines for 5 days at temperature of 28°C (http://www.atcc.org). The virus 
supernatant is then filtrated, concentrated, and purified using sucrose gradient method 
upon harvest. The UV-inactivated virus aliquots are stored at -80°C. 
 
Antibody detection in the sera by ELISA 
 
The detection of dengue-reactive antibody in the sera by ELISA will be performed. In 
brief, ELISA plates will be coated with 75 ng/well of purified DENV-2 and 0.1 µg/ 
well of EDIII in 50mM Bicarbonate Buffer (pH 9.6) overnight at 4°C. Following 
blocking with PBS-T (1% Tween-20 (vol/vol)) + 3% milk (wt/vol) + 2% FCS for 1 hr 
at room temperature, washing with PBS-T, the plates will be incubated for 1 hr at 
room temperature with sera. After five times of washing with PBS-T, the plates will be 
incubated with the secondary antibody (anti-human-HRP conjugated) for 1 hr at room 
temperature, and washed three times with PBS-T and once with PBS. 50 µL of TMB 
substrate will then be added to each well and the reaction allowed to develop for a few 
minutes until blue colour appears. The reaction will then be arrested with 3M HCl and 
the absorbance will be measured at 450 nm on a spectrophotometer (40). 
 
Antibody depletion and Plaque Reduction Neutralization Test (PRNT) 
 
The pre- and post-infection sera will be depleted of EDIII- specific antibodies.  
 
PRNT will be performed to investigate the effects of the EDIII-specific antibodies 
depletion on the capacity of sera in DENV-2 neutralization. Serum binding methods 
will be established with the pre-infection (convalescent) serum prior to the depletion. 
BHK-21 cells will be seeded and cultured in 24-well plates until 90-95% confluent, at 
which the preparation of virus/serum mix (serially diluted sera + 40 Plaque Forming 
Units (PFU) of DENV-2 virus, incubated for one hour at 37°C, 5% CO2) will be 
added. The dilutions made for virus control (VC40 and VC10) are also included. 
Following aspiration of the neutralizing mixture, a nutrient overlay medium (0.8% 
CMC) will be added to each well, and the plates will be incubated for four days at 
37°C, 5% CO2. The cells will be fixed and stained with 1% Crystal Violet. The 
percentage of neutralization will be defined as the reduction in the number of foci in 
the test sera compared to the number of foci in the control wells with normal human 
serum. The determination of the 50% neutralization titre will be performed via non-
linear does-response regression analysis (40).   
 
Inoculation and propagation of DENV-2 in mosquitoes (Refer to Appendix 2) 
 
The infection of the subject with DENV-2 via mosquito bite to obtain the post-
infection serum as outlined above is at present conditional on the IRB approval. Due 
to the low existing titre of subject’s convalescent sera against DENV-2, the vaccine 
(attenuated) strain of DENV-2 (PDK-53) will be used throughout the subsequent 
inoculation and infection procedures to ensure subject’s safety. 
 
The motive of propagation in mosquitoes (natural host) as a source of virus for 
infection is to avoid potential strain properties modification that may occur in 




Procedures on the intrathoracic inoculation and the propagation of the virus in 
mosquitoes, according to Gubler et al. (54, 55) are briefly outlined as such: 
- Immobilization of female mosquitoes using ice water bath. 
- Dilutions of inoculums in PBS, pH 7.4, containing 0.5% Gelatin and 5% HI   
FCS. 
- Calculation of titre: mosquito assay for dengue virus by plaque assay (mosquitoes 
are ground with a mortar and pestle or disintegrated by sonic energy), or 
correlation of the injected amount of virus with the extent of infection of the 
salivary gland cells. RT-PCR and Immunoflourescence Assay (IFA) can also be 
performed to identify the presence and propagation of virus in the infected 
mosquitoes. 
- Maintenance of mosquitoes after inoculation for 7 days at 32°C to allow 
adequate replication of virus (the rate of virus replication is dependent on 
temperature).  
- For the infection of the subject, infected female mosquitoes will be used within 
the secure BSL2 insectaries at Duke-NUS. The lab is only accessible by access 
card 24/7 and follows safety practice guidelines. 
 
Generation of a human immune Fab-phage library using Phage display technology 
 
An immune Fab-phage library will be constructed using phage display. The V-genes 
will be derived from the IgG mRNA of B-cells extracted from an acutely infected 
subject’s peripheral blood lymphocytes (whose immune library will be expectantly 
enriched in antigen-specific antibodies).  
 
The antibody genes will be cloned using reverse transcription of the mRNA, 
amplification by PCR and assembly into a single gene (56). The assembled DNA 
fragment will then be inserted into a phagemid vector and the recombinant phagemid 
is introduced into competent E.coli. Phagemid-containing bacterial cells will be grown 
and subsequently infected with an M13 helper phage to yield recombinant phages that 
display antibody fragments as fusion to one of the phage coat proteins.  
 
Identification of strongly neutralizing human monoclonal antibodies 
 
By bio-panning, the antibody libraries will be screened and enriched for antigen-
specific clones by incubating the phages with an immobilized DENV-2 virus. 
Unbound phages are removed by washing whereas the Fab-phage clones with 
specificity for DENV-2 will be eluted and amplified in E.coli.  
 
Following the identification of DENV-2- specific Fab from the immune Fab-phage 
library, unique Fab phage will be subject to DNA fingerprinting and sequencing. 
Subsequently, Fab will be cloned out of phage construct and expressed recombinantly 
in E.coli. Finally, the biochemical and cell-based assays characterization (PRNT with 
promising Fab) of Fab/ IgG will be performed to yield strongly neutralizing DENV-2-
specific human monoclonal antibodies. 
 
Upon consent, medical and relevant clinical information will be obtained from the 
participant. An initial blood sample will be taken before the infection procedure. 
 
Infection of subject with DENV-2 (vaccine strain, PDK-53) by laboratory-infected 
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mosquitoes will also be performed at subsequent occasion, followed by collection of 
30mL blood sample on D0 (Collection 1 post-infection). 
 
a. Study Visits and Procedures 
 
Blood samples will be taken again at: 
D3 post-infection: collection 2 
D5 post-infection: collection 3 
D7 post-infection: collection 4 
D10 post-infection: collection 5 
D12 post-infection: collection 6 
D14 post-infection: collection 7 
D60 post-infection: collection 8 
 
On the days of blood collection, some data on potential symptoms will be collected 
respectively (example shown below). 
 
Day Symptoms (0=none, 1=mild, 2=moderate, 3=severe) 
0 Fever: ____°C 
 
Malaise          0  1  2  3                Headache      0  1  2  3 
Rash              0  1  2  3                Arthralgia      0  1  2  3 
3 Fever: ____°C 
 
Malaise          0  1  2  3                Headache      0  1  2  3 




4.2 If samples of body fluids or tissues are taken as part of this research, state the amount and 
frequency at which these samples are taken. Will these samples be stored? If so, please 
include details in section 5.3. 
30 ml blood each time. 
D0 :Baseline 
D3 post-infection: collection 2 
D5 post-infection: collection 3 
D7 post-infection: collection 4 
D10 post-infection: collection 5 
D12 post-infection: collection 6 
D14 post-infection: collection 7 
D60 post-infection: collection 8 
 




No benefit. Risk is minimal as previous documented infection with DENV-2 provides 
lifelong immunity to the serotype. 
 
4.4 Discuss the potential difficulties and limitations of the proposed procedures and alternative 
approaches to achieve the aims. 
No alternative approaches. No difficulties anticipated as the methods are familiar to the 
study team. 
4.5 Will any part of the procedures be placed on audiotape, film/video, or other electronic 
media?          Yes            x No 
 
If Yes, what is the medium? Explain how the recorded information will be used? How long 
will the tapes, etc, be retained and how will they be disposed of?       
 
5. Additional Information on Methodology: 
 5.1 If research involves databases, please complete the following: 
5.1.1 Where will the data be stored? 
Duke-NUS, Level 9 
5.1.2 Who will have access to the data? 
Only the investigators 
5.1.3 What will happen to the data after research completion? 
Data will be stored for 5 years and then destroyed 
5.1.4 Any other remarks? 
      
 5.2 If research involves placebo, please complete the following: 
5.2.1 Explain what ‘standard of care’ therapy is available for this condition 
NA 
5.2.2 Discuss the ethical implications of using placebo instead of ‘standard of care’ 
therapy in this situation 
      
5.2.3 Address the issues of safety and efficacy of other available therapies 
      
5.2.4 The total duration the subject would be on placebo arm of the research 
      
5.2.5 Greatest potential harm that the subject might be exposed to as a result of not 
receiving effective therapy 
      
5.2.6 Protocols in place to safeguard participants receiving placebo 
      
5.2.7 Any other remarks? 
      
 5.3  If research involves tissues/body fluids, please complete the following: 
5.3.1 Please state the amount and frequency at which these samples are taken. 
30 mL at baseline, 10-20 mL at all other blood taking 
Blood will be taken on D3, 5, 7, 10, 12, 14 and 60 
5.3.2 Describe the biological samples that will be collected and stored? 
Venous blood 
 
5.3.3 What tests will be performed on these biological samples? 
 
Antibody detection in the sera by ELISA 
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The detection of dengue-reactive antibody in the sera by ELISA will be performed. In 
brief, ELISA plates will be coated with 75 ng/well of purified DENV-2 and 0.1 µg/ 
well of EDIII in 50mM Bicarbonate Buffer (pH 9.6) overnight at 4°C. Following 
blocking with PBS-T (1% Tween-20 (vol/vol)) + 5% milk (wt/vol) + 2% FCS for 1 hr 
at room temperature, washing with PBS-T, the plates will be incubated for 1 hr at 
room temperature with sera. After five times of washing with PBS-T, the plates will be 
incubated with the secondary antibody (anti-human-HRP conjugated) for 1 hr at room 
temperature, and washed three times with PBS-T and once with PBS. 50 µL of TMB 
substrate will then be added to each well and the reaction allowed to develop for a few 
minutes until blue colour appears. The reaction will then be arrested with 3M HCl and 
the absorbance will be measured at 450 nm on a spectrophotometer (40). 
 
Antibody depletion and Plaque Reduction Neutralization Test (PRNT) 
 
The pre- and post-infection sera will be depleted of EDIII- specific antibodies.  
 
PRNT will be performed to investigate the effects of the EDIII-specific antibodies 
depletion on the capacity of sera in DENV-2 neutralization. Serum binding methods 
will be established with the pre-infection (convalescent) serum prior to the depletion. 
BHK-21 cells will be seeded and cultured in 24-well plates until 90-95% confluent, at 
which the preparation of virus/serum mix (serially diluted sera + 40 Plaque Forming 
Units (PFU) of DENV-2 virus, incubated for one hour at 37°C, 5% CO2) will be 
added. The dilutions made for virus control (VC40 and VC10) are also included. 
Following aspiration of the neutralizing mixture, a nutrient overlay medium (0.8% 
CMC) will be added to each well, and the plates will be incubated for four days at 37°C, 
5% CO2. The cells will be fixed and stained with 1% Crystal Violet. The percentage of 
neutralization will be defined as the reduction in the number of foci in the test sera 
compared to the number of foci in the control wells with normal human serum. The 
determination of the 50% neutralization titre will be performed via non-linear does-
response regression analysis (40). 
 
5.3.4 What will happen to the biological samples after the research is completed? 
 
Will be stored for 5 years and then destroyed 
 
5.3.5 How are the biological samples identified? 
  
 No Identifier 
 Biological samples are coded and the code is maintained with the PI 
x Identifiers present 




5.3.6 Will results from the tests be communicated to the subjects? 
 
The subject is Prof Duane Gubler, an expert in the field of dengue. He has known 
previous infection with DENV serotype 2. 
 
5.3.7 Any other remarks? 
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 5.4  If research involves human samples/ tissues/ cell cultures/cell lines, please 
complete the following: 
 
5.4.1 Describes the samples/ cells that will be used for the research. 
      
Indicate if tissues / cell cultures are:  
(Please tick) 
Type of Human 
Tissues/ Samples 
 
Name of Human 
Cell Lines (e.g. 
HeLa) 
Source & Catalog 
No. (e.g. ATCC, 
CCL-2)   
Quantity  
Primary Secondary 
      
      
      
 
5.4.2 Indicate the source of the cell cultures/lines. Please provide proof of purchase or 
catalog details of the cells. 
      
 5.5 If research involves archived tissues or data from the Department, approval from 
the custodian is required. The custodian is the Head of Department (HOD) or Chairman 
Medical Board (if PI is the HOD). 
(An email/letter from the HOD or Chairman Medical Board, stating his approval to supply 
the quantity of tissues for each type, or the data, would suffice.) 
6. Characteristics of Target subjects / Target Subject Data: 
6.1 What is the number of subjects to be enrolled? Give a breakdown by institution for multi-
center studies. 
Institution/Site of Recruitment Total Males Females Children 
NUS 1 1 0 0 
 
6.2 Lower Age Limit: 18                                  Upper Age Limit: none 
 
6.3 Total number of subjects targeted for enrolment worldwide (for international studies): 1 
6.4 Are there any subject recruitment restrictions based on race of the subject? 
no 
6.5 Inclusion criteria 
Documented previous infection with dengue serotype 2 and positive PRNT result 
against DENV serotype 2 
6.6 Exclusion criteria 
Not applicable 
6.7 Are the subjects vulnerable or in a dependent relationship with the researchers?  
             Yes              No             x Not applicable 
If Yes, please provide details.  
The subject is the Head of the EID program, a well-known dengue expert. He is not in 
a dependent relationship with the investigators.  
 
7. Participant Information Sheet and Written Informed Consent Form: 
7.1 The PI is responsible for ensuring that all research subjects give informed consent before 
enrolling into the research. Please submit a copy of the Participant Information Sheet and 
Consent Form.  
(A sample of Participant Information Sheet and Consent Form is available on the IRB 
website at http://www.nus.edu.sg/irb/Guide.htm) 
7.2 Summarise the consent procedure. Please specify when consent will be obtained and who 
will obtain consent. 
A patient information sheet and consent form will be given to the subject. The PI will 
obtain consent. Consent will be done before the commencement of the study and after 
IRB approval. 
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7.3 If waiver of consent is required, please justify if your research meets the following 
criteria: 
(The NUS-IRB may waive the requirement to obtain informed consent if the NUS-IRB finds that the 
research meets the following 4 criteria.) 
 
7.3.1 The research involves no more than minimal risk to the subjects. 
      
7.3.2 The waiver or alteration will not adversely affect the rights and welfare of the 
subjects. 
      
7.3.3 Whenever appropriate, the subjects will be provided with additional pertinent 
information after participation. 
      
7.3.4 The research could not practicably be carried out without the waiver or alteration. 
      
8. Recruitment Process: 
8.1 Explain the process of recruitment in detail. For example state how the list of potential 
research subjects will be obtained e.g. from attending doctor who will refer potential 
subjects. Please submit a copy of any advertisements/posters that will be used. 
Not applicable 
8.2 Will subjects be chosen from medical records? If so, how will you obtain names and NRIC 
Nos of subjects and from whom will you obtain permission for use of these records? 
No 
9. Data Safety Monitoring Plan  (for clinical trials only): 
• Please include details on the Data Safety Monitoring Plan (DSMP) for the research. Please 
discuss the plans in place to ensure the safety and well being of subjects, and integrity of 
the data collected.  
      
10. Timelines: 
10.1 What are the estimated start and end dates of the research? 
Start Date: June 2010       End Date: Feb 2011 
 
10.2 Indicate the duration of subject involvement in the research. Please also state the 
recruitment period.  
60 days 
11. Financial Aspects/Conflicts of Interest: 
11.1 Who will be responsible for research related costs? For sponsored research, list the costs 
that will be borne by the sponsor.  
Duke-NUS GMS, EID program 
11.2 For industry sponsored research, please complete the following. 
11.2.1 Name of the sponsor company? 
      
11.2.2 Address of the sponsor? 
      
11.2.3 Sponsor contact person? 
      
11.2.4 Have any of the investigators received any financial support, sponsorship from 
the company supporting this research?      Yes    No 
 
11.2.5 Do any of the investigators hold any ownership interest, e.g. stock options in this 
company?                                                Yes  No 
 
11.2.6 Is the sponsor offering any incentive connected with subject recruitment or 
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completion of research (e.g. finders’ fee, recruitment bonuses etc) that will be 
paid to the research staff?                         Yes  No 
 
11.2.7 If you have answered ‘yes’ to Q 5, please elaborate. 
      
11.2.8 Any other remarks? 
      





VII. ATTACHMENT CHECKLIST:  
Document 
 
Attached? Not Applicable? 
Research Protocol (latest version)*+ x  
Grant Application Form  x 
Participant Information Sheet and Consent Form+ x  
Investigator(s)’ CV x  
Investigator Brochure  x 
Survey Form(s)/Questionnaire(s) / Diary Card+  x 
Data Collection Form+  x 
Catalog Details / Proof of Purchase of Cell Cultures or Lines  x 
Advertisement for Recruitment of Subjects+  x 
Letter of Invitation to Subjects+  x 
Letter to Doctors Requesting Referral   x 
Relevant Publications x  
Cheque for Industry Sponsored Trials  x 
Subject Payment Details*  x 
Subject Compensation Details*  x 
Financial Agreement  x 
GCP/CITI Training Certificate of PI  x  
 
+Version number and date is required. 









































DATE OF BIRTH: 
 
 
Previous dengue (or flavivirus) infections 
 
  








Infecting strain known?       Y/N 
If yes, please describe………… 
…………………………………… 
 
Likely cause  
(please tick appropriate box): 
☐ Work related  
    Please describe…………….. 
    ………………………………… 
    Where was the virus isolated 
from?..................................... 
    Do you remember how many 
times you were bitten? …….. 




☐ Serology test 
☐ Others 
Please describe the kits used     











For how many days? .......... 
 




Did you have any of the following: 
• Rash                                          Y/N 
• Backache or headache              Y/N 
• Bleeding                                     Y/N 
             If you had bleeding, please describe 
             …………………………………………………………….. 
             …………………………………………………………….. 
• Nausea                                      Y/N 
• Diarrhoea                                   Y/N 
• Vomiting                                     Y/N 
• Lethargy                                     Y/N 
• Swollen glands                          Y/N 
• Loss of appetite                         Y/N 
• Increased skin sensitivity           Y/N 
• Others……….. 
 
For how many days were you unable to work?.......... 
 
Did you consult a doctor?                         Y/N 
Were you hospitalized?                            Y/N 
If yes, for how long?............ 
Did anyone in your household get infected?          Y/N 
 
Any long-term sequelae (symptoms) after recovery from infection? Y/N 







Infecting strain known?       Y/N 
If yes, please describe………… 
…………………………………… 
 
Likely cause  
(please tick appropriate box): 
☐ Work related  
    Please describe…………….. 
    ………………………………… 
Fever Y/N 
For how many days? .......... 
 




Did you have any of the following: 
• Rash                                          Y/N 
• Backache or headache              Y/N 
• Bleeding                                     Y/N 
             If you had bleeding, please describe 
             …………………………………………………………….. 
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    Where was the virus isolated 
from?..................................... 
    Do you remember how many 
times you were bitten? …….. 




☐ Serology test 
☐ Others 
Please describe the kits used     






             …………………………………………………………….. 
• Nausea                                      Y/N 
• Diarrhoea                                   Y/N 
• Vomiting                                     Y/N 
• Lethargy                                     Y/N 
• Swollen glands                          Y/N 
• Loss of appetite                         Y/N 
• Increased skin sensitivity           Y/N 
• Others……….. 
 
For how many days were you unable to work?.......... 
 
Did you consult a doctor?                         Y/N 
Were you hospitalized?                            Y/N 
If yes, for how long?............ 
Did anyone in your household get infected?          Y/N 
 
Any long-term sequelae (symptoms) after recovery from infection? Y/N 








Infecting strain known?       Y/N 
If yes, please describe………… 
…………………………………… 
 
Likely cause  
(please tick appropriate box): 
☐ Work related  
    Please describe…………….. 
    ………………………………… 
    Where was the virus isolated 
from?..................................... 
    Do you remember how many 
times you were bitten? …….. 




☐ Serology test 
☐ Others 
Please describe the kits used     









For how many days? .......... 
 




Did you have any of the following: 
• Rash                                          Y/N 
• Backache or headache              Y/N 
• Bleeding                                     Y/N 
             If you had bleeding, please describe 
             …………………………………………………………….. 
             …………………………………………………………….. 
• Nausea                                      Y/N 
• Diarrhoea                                   Y/N 
• Vomiting                                     Y/N 
• Lethargy                                     Y/N 
• Swollen glands                          Y/N 
• Loss of appetite                         Y/N 
• Increased skin sensitivity           Y/N 
• Others……….. 
 
For how many days were you unable to work?.......... 
 
Did you consult a doctor?                         Y/N 
Were you hospitalized?                            Y/N 
If yes, for how long?............ 
Did anyone in your household get infected?          Y/N 
 
Any long-term sequelae (symptoms) after recovery from infection? Y/N 















Post-infection: Blood collection  
 
Day Symptoms (0=none, 1=mild, 2=moderate, 3=severe) 
0 Fever: ____°C 
 
Malaise          0  1  2  3                Headache      0  1  2  3 
Rash              0  1  2  3                Arthralgia       0  1  2  3 
 
 3 Fever: ____°C 
 
Malaise          0  1  2  3                Headache      0  1  2  3 
Rash              0  1  2  3                Arthralgia       0  1  2  3 
 
5 Fever: ____°C 
 
Malaise          0  1  2  3                Headache      0  1  2  3 
Rash              0  1  2  3                Arthralgia       0  1  2  3 
 
7 Fever: ____°C 
 
Malaise          0  1  2  3                Headache      0  1  2  3 
Rash              0  1  2  3                Arthralgia       0  1  2  3 
 
10 Fever: ____°C 
 
Malaise          0  1  2  3                Headache      0  1  2  3 
Rash              0  1  2  3                Arthralgia       0  1  2  3 
 
12 Fever: ____°C 
 
Malaise          0  1  2  3                Headache      0  1  2  3 
Rash              0  1  2  3                Arthralgia       0  1  2  3 
 
14 Fever: ____°C 
 
Malaise          0  1  2  3                Headache      0  1  2  3 
Rash              0  1  2  3                Arthralgia       0  1  2  3 
 
60 Fever: ____°C 
 
Malaise          0  1  2  3                Headache      0  1  2  3 




















GUIDELINES ON PARTICIPANT  




1. Project title  
Characterization of the Antibody Repertoire in a Dengue Virus 2- Immune 
Subject Following Re-exposure to the Same Serotype. 
 
2. Principal Investigator and co-investigator(s), if any, with the contact 
number and organization. 
PI 
Assoc. Prof Annelies Wilder-Smith 




Assoc. Prof. Subhash Vasudevan 
Program in Emerging Infectious Diseases, Duke-NUS Graduate Medical 
School 
E-mail: subhash.vasudevan@ duke-nus.edu.sg 
 
3. What is the purpose of this research? 
 
You are invited to participate in a research. This information sheet provides 
you with information about the research. The Principal Investigator (Assoc. 
Prof. Annelies Wilder-Smith) will also describe this research to you and 
answer all of your questions. Read the information below and ask questions 
about anything you don’t understand before deciding whether or not to take 
part. 
You are invited because of your known history of multiple dengue virus 
infections, and hence the existing immunity to the different serotypes.  
This study is carried out to determine if there is any difference in antibody 
distribution and potential boosting of homotypic antibodies following re-
exposure to the antigen through a natural route of infection. In this respect, the 
study is unique. 
 
4. Who can participate in the research? What is the expected duration of my 
participation? What is the duration of this research? 
This study will recruit 1 subject from Duke-NUS Graduate Medical School 
(PI’s Institution) over a period of one year. Specifically this study will involve 
you, Professor Duane J. Gubler, Program Director of the Signature Program in 
Emerging Infectious Diseases Program. 
 
As a world-leading expert in dengue research you are fully aware that primary 
infection by a serotype of DENV leads to life-long protection to that serotype. 
You are aware that this study will expose you to DENV-2 using laboratory- 
infected female Aedes aegypti mosquitoes. The mosquitoes will be inoculated 
with DENV-2 serotype to which you have natural antibodies based on your 
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record of virus isolation following a natural infection in 1973, as well as 
independent laboratory verification at Duke-NUS GMS 
 




6. What will be done if I take part in this research? 
Your participation in the study will last one year. If you agree to take part in 
this study, the following will happen to you: 
Initial collection of blood sample to obtain pre-infection (convalescent) serum, 
for the purpose of the independent laboratory verification. 
The laboratory test (Plaque Reduction Neutralization Test) showed that your 
70% neutralization titre against DENV-2 is relatively low (1:40). Therefore, 
due to this reason, all the procedures involved in the immune challenge 
(mosquito inoculation and mosquito feeding on subject) will use the vaccine 
(attenuated) strain of DENV2 (PDK-53) to ensure your safety. 
Infection by laboratory- infected mosquitoes: 5-10 infected female mosquitoes 
will be picked for feeding on subject (full blood meal). Subject’s arm will be 
examined prior to placing in the insect chamber. Photograph record of skin 
before and after bite will be taken. 
           Collection of blood samples over the course of 60 days post-infection: 
 D0 (pre-infection): collection 1 
 D3 post-infection: collection 2 
 D5 post-infection: collection 3 
 D7 post-infection: collection 4  
 D10 post-infection: collection 5 
 D12 post-infection: collection 6 
 D14 post-infection: collection 7 
 D60 post-infection: collection 8 
In total, 8x30 mL= 240mL of blood will be taken post-infection as part of this 
study.  
On the days of blood collection, some data on potential symptoms will be 
collected respectively (example shown below). 
 
Day Symptoms (0=none, 1=mild, 2=moderate, 3=severe) 
0 Fever: ____°C  
Malaise          0  1  2  3                Headache      0  1  2  3 
Rash              0  1  2  3                Arthralgia       0  1  2  3 
3 Fever: ____°C  
Malaise          0  1  2  3                Headache      0  1  2  3 
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7. If biological samples are taken, what will be done with my samples?  
 
30ml of blood will be taken in each venipuncture. 8 venipunctures will be 
performed within 60 days (total: 240ml). The samples taken will be used 
solely for this research and will be destroyed after the completion of the 
research.  
Data collected and entered into the Case Report Forms are the property of 
Duke-NUS Graduate Medical School.  
 
8. How will my privacy and the confidentiality of my research records be 
protected? 
Information collected for this study will be used in scientific publication in 
peer-reviewed journals.  Your contribution and expertise in entomology and 
the use of mosquitoes to carry out the infection will be appropriately 
acknowledged. 
Data collected and entered into the Case Report Forms are the property of 
Duke-NUS Graduate Medical School.  
 
9. What are the possible discomforts and risks for participants? 
Obtaining blood can cause pain, bleeding, bruising, or swelling at the site of 
the needle stick. Fainting sometimes occurs and infection rarely occurs. The 
insect bite may cause local irritation and itchiness. 
 
10. What is the compensation for any injury? 
The only injury that can occur in this study is from the insect bite or during 
blood withdrawal. The risks are minimal and appropriate compensation will be 
provided by the host institution without any legal commitment. Expert 
phlebotomist will perform the blood withdrawal to further minimize the risks 
and discomfort, and Prof. Wilder-Smith will monitor subject safety. 
By signing this consent form, you will not waive any of your legal rights or 
release the parties involved in this study from liability for negligence. 
 
11. Will there be reimbursement for participation? 
 
There is no reimbursement for participation in this study. 
 
12. What are the possible benefits to me and to others?  
 
There is no direct benefit to you by participating in this research. The 
knowledge gained will benefit the public in the future. Your participation in 
this study may add to the scientific knowledge about the antibody repertoire 
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generated during re-exposure to a dengue virus serotype for which you already 
are known to be immune. 
 
13. Can I refuse to participate in this research? 
 
Yes, you can. Your decision to participate in this research is voluntary and 
completely up to you. You can also withdraw from the research at any time 
without giving any reasons, by informing the principal investigator. 
 
14. Whom should I call if I have any questions or problems? 
 
Please contact the Principal Investigator,  
 
Assoc. Prof. Annelies Wilder-Smith  






Assoc. Prof. Subhash Vasudevan 
Emerging Infectious Diseases Program, Duke-NUS Graduate Medical School  
E-mail: subhash.vasudevan@duke-nus.edu.sg   
Contact number: + 65 65166718 
 
for all research-related matters and in the event of research-related injuries. 
 
For an independent opinion regarding the research and the rights of research participants, you may 
contact a staff member of the National University of Singapore Institutional Review Board (Attn: 

























Project title:  
Characterization of the Antibody Repertoire in a Dengue Virus 2- Immune Subject 
Following Re-exposure to the Same Serotype. 
 
Principal Investigator with the contact number and organization: 
I hereby acknowledge that: 
1. My signature is my acknowledgement that I have agreed to take part in the 
above research.  
2. I have received a pamphlet (or a copy of this information sheet) that explains 
the use of my [blood/data] in this research. I understand its contents and agree 
to donate my [blood/data] for the use of this research. 
3. I can withdraw from the research at any point of time by informing the 
Principal Investigator and all my [blood/data] will be discarded. 
4. I will not have any financial benefits that result from the commercial 
development of this research. 
5. (If applicable) I agree to the use of my medical records for this research. 
* This research has been explained to me in _________________ (state language), 













* Name and Signature (Translator) Date  
 
 
I agree/do not agree* for the following personal identifiers to be disclosed in the 
scientific publications that arise in future :  
 
_________________  _______________ 
Last Name                   First name                      
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Organisation Name:                          
 
Position:   
 
 






*(Please include this section if the subject is unable to understand English and read any of the translated consent 
documents available.) 
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For Principal Investigator’s Information Only 
 
(US FDA §46.116) 
General requirements for informed consent  
(a) Basic elements of informed consent. Except as provided in paragraph (c) or (d) of this 
section, in seeking informed consent the following information shall be provided to each 
subject: 
(1) a statement that the study involves research, an explanation of the 
purposes of the research and the expected duration of the subject's 
participation, a description of the procedures to be followed, and 
identification of any procedures which are experimental; 
(2) a description of any reasonably foreseeable risks or discomforts to the 
subject; 
(3) a description of any benefits to the subject or to others, which may 
reasonably be expected from the research; 
(4) a disclosure of appropriate alternative procedures or courses of treatment, 
if any that might be advantageous to the subject; 
(5) a statement describing the extent, if any, to which confidentiality of 
records identifying the subject will be maintained; 
(6) for research involving more than minimal risk, an explanation as to 
whether any compensation and an explanation as to whether any medical 
treatments are available if injury occurs and, if so, what they consist of, or 
where further information may be obtained; 
(7) an explanation of whom to contact for answers to pertinent questions 
about the research and research subjects' rights, and whom to contact in the 
event of a research-related injury to the subject; and 
(8) a statement that participation is voluntary, refusal to participate will 
involve no penalty or loss of benefits to which the subject is otherwise 
entitled, and the subject may discontinue participation at any time without 
penalty or loss of benefits to which the subject is otherwise entitled. 
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(b) Additional elements of informed consent. When appropriate, one or more of the following 
elements of information shall also be provided to each subject: 
(1)  a statement that the particular treatment or procedure may involve risks 
to the subject (or to the embryo or fetus, if the subject is or may become 
pregnant) which are currently unforeseeable; 
(2) anticipated circumstances under which the subject's participation may be 
terminated by the investigator without regard to the subject's consent; 
(3) any additional costs to the subject that may result from participation in the 
research; 
(4) the consequences of a subject's decision to withdraw from the research 
and procedures for orderly termination of participation by the subject; 
(5) a statement that significant new findings developed during the course of 
the research which may relate to the subject's willingness to continue 
participation will be provided to the subject; and 





























Sequence alignment results between the E protein Ectodomain III of  DENV-2 



















      Single nucleotide change
Alignment between DENV2 TSV01 and PDK53 EDIII 
aa 291-395 (105 aa) 
TSV01 
PDK-53 
TSV01 
PDK-53 
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